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This dissertation (a) detailed the optimal imaging times and quantifiable intervals of the 
non-toxic tumor surrogate marker D-luciferin in metastatic and primary brain tumors, (b) 
characterized the creation, passive permeability, efflux pump status, and vascularity of a 
widely-used EGFR-mutant lung cancer cell line, (c) evaluated the in-vitro cytotoxicity 
and in-vivo efficacy of three novel chemotherapeutic agents on brain metastases of lung 
and breast cancer as well as primary glioblastoma, and (d) provided a review of the 
current clinical and preclinical treatment options for breast cancer and lung cancer brain 
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It is odd to think of cancer as a unifier, but in some ways, it is. Cancer has remained 
the second-most common cause of death since the 1980s, disregarding sex, ethnicity, 
race, or characteristics otherwise. [1] In 2016, cancer was responsible for nearly 600,000 
deaths, and with life expectancy increasing, the incidence of cancer diagnosis and deaths 
have also increased. [1] In women breast cancer is most common, while in men prostate 
cancer is most common; in both genders this is followed by lung cancer and colorectal 
cancer. [2] For cancer deaths, in both men and women lung cancer is first, followed by 
prostate cancer or breast cancer, respectively, and then colorectal cancer. [2]  
Cancer within its tissue of origin is defined as “primary”, spreading to other organs in 
a process known as metastasis. [3] It is metastasis that is responsible for the lethality of 
cancer and the magnitude of cancer death. [4] While cancer may metastasize to any 
location, the highest incidence of metastases occurs in the lung, liver, bone, brain, and 
adrenal glands. [5] Depending on cancer type, approximately 10 to 50% of all cancer 
patients will eventually develop a metastasis. [6-8] 
Treatments for metastases are dependent on tumor location but generally involve a 
regimen of radiation, surgery, and chemotherapy. Brain metastases becomes increasingly 
challenging to treat due to the physiochemical blood-brain barrier chemotherapy is 
limited in its cytotoxic ability, and in combination with the invasiveness of resection. [9] 
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Once diagnosed with brain metastases, the median survival typically ranges from three 
months to two years. [10] 
Fortunately, novel chemotherapeutic agents, redesigned dosage forms, and new 
methods of drug administration have allowed for modest improvement of survival in 
brain metastases. These new agents often act as antagonists of a pathway upregulated in 
cancer cells (such as osimertinib, which inhibits the EGFR signaling pathway), prolong 
and enhance cytotoxic effects by conjugation to linker molecules (such as etirinotecan 
pegol, which is a tetramer of irinotecan linked by polyethylene glycol chains), or avoid 
efflux pumps to penetrate the brain and tumor (such as Doxil, which is a pegylated 
liposomal version of doxorubicin). Trends have shown that more molecules are being 
developed with the intent to cross the blood-brain and blood-tumor barriers to treat brain 
metastases. 
In this dissertation, we investigate the effect of novel chemotherapeutic agents 
compared to standard-of-care chemotherapy on median survival of two models of brain 
metastases and one model of glioblastoma. We additionally correlate in vitro toxicity 
assays to in vivo drug efficacy and characterize the optimal timing for luciferin 
bioluminescence quantification and its surrogacy for tumor burden in response to 
chemotherapy. As our laboratory has extensively characterized the blood-tumor barrier of 
breast cancer brain metastases [6], initial characterization of the blood-tumor barrier of a 
EGFR-mutated lung cancer brain metastases model is described. Effects of 
chemotherapeutic agents on barrier vascular integrity and efflux pumps are visualized 
using fluorescence and autoradiography data.  
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Chapter 2 reviews the epidemiology, subtypes, prognostic factors, and survival 
characteristics of brain metastases from breast cancer and lung cancer, as well as primary 
glioblastoma. Conventional chemotherapeutic regimens, novel chemotherapy, and in-trial 
agents are also discussed. 
Chapter 3 details optimal pharmacokinetic timing for luciferin imaging for breast-
brain, lung-brain, and glioblastoma models used subsequently for the rest of these 
dissertation experiments. 
Chapter 4 describes the survival effects of pegylated irinotecan (etirinotecan pegol) in 
three models of breast cancer brain metastases. Etirinotecan pegol is hypothesized to 
have preferential accumulation in tumors due to the vasculature leakiness, and may 
additionally bypass efflux transporters. In vitro toxicity effects as well as in vivo survival 
effects of etirinotecan pegol are compared to BEACON trial agents for the respective 
models. Bioluminescence curves are similarly compared for treatment groups.  
Chapter 5 illustrates the creation of the PC-9-Br EGFR brain-seeking lung cancer cell 
line. Luciferin kinetics reveal the best range of time for in vivo imaging to assess tumor 
burden and response to treatments. Fluorescence of tomato red (tumor), Oregon Green 
(efflux pump), and indocyanine green (vascularity) characterize the environment of lung 
cancer brain metastases, and effects of chemotherapy on this environment. The effects of 
the permeability glycoprotein efflux pump at the blood-tumor barrier is visualized and 
inhibited to show its contribution to chemotherapy restriction. Autoradiography data 




Chapter 6 depicts the survival effects of etirinotecan pegol in the EGFR-mutated 
PC9-Br model of lung cancer brain metastases. In vitro toxicity assays of BEACON 
agents, as well as conventional chemotherapy used to treat lung cancer, show sensitivity 
and estimated response of the PC9 line to treatments. Results of survival and 
bioluminescence are compared to cellular sensitivity. The differences in permeability, in 
vitro toxicity, and in vivo survival are discussed, especially in the context of EGFR-
targeted tyrosine kinase inhibitors. 
Chapter 7 reports the survival effects of etirinotecan pegol in the setting of primary 
gliobastoma. In contrast to brain metastases models, the glioblastoma model uses 
intracranial injections and a slower-growing tumor, which may favor chemotherapy 
deposition. 
Chapter 8 describes the in vitro and in vivo effects of nano-albumin-bound paclitaxel 
and pegylated liposomal docetaxel on the triple negative breast cancer and lung cancer 
models. Chapter 7 and Chapter 8 feature preliminary data, with in vivo comparisons to 
conventional chemotherapy ongoing. 
In summary, this dissertation evaluates the current treatment strategies and effects of 
three novel chemotherapeutic agents featuring enhanced brain permeability on the 
survival of preclinical brain metastases and primary lesions. This dissertation also 
characterizes the vascular integrity, passive permeability, efflux pump contribution, and 
overall environment of brain metastases of EGFR-mutant lung cancer, which provides 
insight into why patients on chemotherapy often have relapsing lesions. When viewed 
altogether, the data emphasizes a multifocal approach to improve penetrance of 
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chemotherapy by molecular design or innovative formulation, with the goal of 
minimizing damage to normal brain parenchyma surrounding tumors. 
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CURRENT TREATMENT STRATEGIES FOR LUNG CANCER AND 
BREAST CANCER BRAIN METASTASES AND GLIOBLASTOMA 
 
2.1 Breast Cancer Epidemiology 
Breast cancer remains the most common malignancy in women. Over an 80-year 
lifetime, the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
reports from 2003 to 2007 report the absolute risk of a woman developing breast cancer 
is 1-in-8 (12%), which is a modest increase from the lifetime risk in the 1970s of 
approximately 1-in-10 (10%). [1] The strongest risk factor for developing breast cancer is 
age, with incidence increasing as age increases. [1] In their 30s, women have less than 
1% risk of developing breast cancer, yet in their 70s the risk increases to nearly 4%. [1] 
Other risk factors that increase the incidence of breast cancer include family history of 
breast cancer, early menstruation, late menopause, use of hormonal therapy, obesity, 
Caucasian race, physical inactivity, excessive alcohol intake, smoking, radiation therapy 
of the chest, and inherited genetic mutations. [1] 
In 2017, it is estimated that more than 250,000 new cases of breast cancer will be 
diagnosed and more than 40,000 women will die from breast cancer. [2] From 1989 to 
2015, the overall death rates of breast cancer decreased by 39% and from 2006 to 2015 in 
all racial and ethnic groups. [2] The rapid decline in mortality is attributed to improved 
screening via early mammography and the widespread use of chemotherapy. [2] The 
seminal discovery of human epidermal growth factor receptor 2 (HER2) presence in up to 
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30% of breast tumors (as well as high levels in other tumor locations) in the mid-1980s 
lead to the production of Herceptin (trastuzumab), the first antibody against HER2. [3] 
This discovery significantly contributed to the rapid mortality reduction from breast 
cancer, as well as introduced a new risk factor for breast cancer metastasis. A conundrum 
formed: while non-specific chemotherapy and targeted therapy such as trastuzumab may 
provide primary control of breast cancer, these agents do not readily achieve adequate 
cytotoxic concentrations in the brain, and allow seeding into the brain and brain 
metastases development. [4] With the discovery of HER2, the molecular subtype of 
breast cancer was found to influence formation of brain metastases as well as overall 
prognosis.  
2.1.1 Breast Cancer Subtypes 
Breast tissue is responsive to hormones such as estrogen and progesterone as part 
of normal physiologic mechanisms. While estrogen stimulates growth of the ductal tissue 
components, lobular development is driven by progesterone. [5] Dysregulations of the 
estrogen receptor (ER), progesterone receptor (PR), and their signaling pathways have 
been attributed to development of breast cancer and are termed “hormone receptor 
positive”. [6] With the incorporation of HER2 as both a risk factor and prognostic factor, 
the hormone receptor breast cancer split into two further types: Luminal A and Luminal 
B.  
Luminal A represent tumors that are ER and PR positive, but do not possess 
HER2 upregulation (are HER2 negative), while Luminal B tumors retain ER, PR, and 
HER2 positivity. [7] Luminal A remains the most common type of primary breast cancer 
with over 50% of total diagnosis, and possesses a good prognosis. Luminal B tumors, due 
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to their positivity of HER2, are more proliferative and require more intensive therapy. [7] 
When tumors are ER and PR negative but retain HER2 positivity, they are simply 
referred to as “HER2” or a breast cancer that has “HER2 over-expression”.  
On the opposite side, it is possible for breast cancer to possess neither hormone 
receptors nor HER2 positivity (ER, PR, HER2-) and are termed “triple negative”. [7] 
These tumors mimic basal epithelial cells and thus the triple negative subtype is often 
termed “basal”. [7] Since there is no receptor to target, triple negative breast cancer 
tumors are more aggressive in growth and systemic therapy is often significantly 
deleterious. These tumors occur in younger patients and are associated with lower 
survival rates and increased relapse rates compared to luminal subtypes.[7] It is logical 
then that the aggressiveness of HER2 and the de-differentiation of triple negative tumors 
allows for enhanced metastases. The discovery of HER2 lead to better treatment 
modalities, and the recent discovery of checkpoint inhibition pathways seeks to do 
similarly.  
The programmed death receptor (PD) and PD ligand-1 or -2 (PD-L1, PD-L2) is 
thought to play a crucial role in cancer developing immunological resistance. [8] 
Expressed on the surface of tumor cells, PD-L1 bind to PD (also known as B7-H1 or 
CD274) expressed on T-cells, B-cells, and natural killer cells. [8, 9] This interaction 
suppresses T-cell activities such as migration and cytotoxic substance secretion, thus 
allowing tumor cells to both escape immune functions. [8] PD-L1 is expressed in 
approximately 20% of TNBC [10] and is attributed with metastatic potential and 
enhanced proliferation. [11, 12] As TNBC has no ER, PR or HER2+ to target, PD-L1 has 
been of great interest to treat triple negative BCBM. 
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Within the scope of brain tumors, patients with triple-negative and HER2+ 
subtypes are at higher risk for formation of brain metastases. [13] 
2.1.2 Breast Cancer Brain Metastases 
As survival from primary breast cancer tumors increase, the rate of developing 
brain metastases also increases. Breast cancer is the second most common cause of brain 
metastases, with breast cancer subtype being an important prognostic factor. The basal or 
triple negative subtype causes >25% of all breast cancer brain metastases (BCBM), 
closely followed by HER2 at approximately 20%. [14] It is approximated that up to 50% 
of all patients diagnosed with HER2 or triple negative breast cancer will eventually 
develop brain metastases. [15] Treatment for BCBM is restricted to surgical resection, 
whole brain radiation therapy, stereotactic radiosurgery, and depending on subtype, either 
targeted chemotherapy or nonspecific chemotherapy. [13, 14] Surgical resection is 
performed via a minimal craniotomy and endoscope, often with patients still awake but 
mildly sedated to monitor integrity of brain functions. [16] Due to the invasiveness of the 
procedure, surgical resection is limited to fewer than 3-4 tumors that are large and 
symptomatic. [17]  
Whole brain radiation therapy (WBRT) is a key therapy option for brain 
metastases in general, with typical doses of 30 Gy in 10 fractions to 37.5 Gy in 15 
fractions producing significant tumor shrinkage and local disease control. [18] WBRT 
can cause significant toxicities such as neurocognitive decline, cataracts, blindness, and 
radiation necrosis. [18] For these reasons, stereotactic radiosurgery (SRS) has been 
promoted as the preferred radiation therapy. SRS is more precise, using multiple beams 
of smaller radiation doses that focus on an area to deliver a cumulative dose. This allows 
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a higher dose per fraction to be administered, leading to better local control rates. [18] 
Despite its reduced neurocognitive decline advantage, SRS is typically only used when 
there are fewer than 4 brain metastases, and studies have shown that survival was not 
superior compared to WBRT, possibly due to lower control of total brain metastatic 
burden. [18] While neurosurgery and radiation techniques are slowly advancing, there is 
an increasing trend to improve brain penetration of existing chemotherapy and to create 
new agents that bypass the blood-brain and blood-tumor barriers.  
2.1.3 Conventional Breast Cancer Brain Metastases Chemotherapy 
Due to limited chemotherapeutic penetration through the blood-tumor and blood-
brain barrier and poor survival statistics, clinical trials have typically excluded patients 
with brain metastases. There are currently no FDA-approved medications specifically 
indicated for brain metastases, though temozolomide and bevacizumab are often 
backbone agents to treating these lesions, and a PCV (procarbazine, lomustine, and 
vincristine) combination is a listed option by the National Cancer Institute. [19] Typical 
systemic therapy includes taxanes (docetaxel, paclitaxel), anthracyclines (doxorubicin), 
platinum compounds (cisplatin), and alkylating agents (cyclophosphamide), often in 
combination with other agents. [20-23] These systemic agents were given for total tumor 
burden control are not intended to treat BCBM specifically.  
Various combinations of cisplatin, etoposide, doxorubicin, 5-fluorouracil, 
methotrexate, vincristine, teniposide, lomustine, irinotecan, gemcitabine, paclitaxel, and 
temozolomide have been trialed in BCBM patients. The success of cisplatin has propelled 
the agent as part of standard non-targeted backbone therapy in combination with other 
agents. Cisplatin and etoposide were tested as combination agents in a Phase II trial of 4 
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BCBM patients in 1997. Only 1 patient had a partial response, leading authors to 
conclude that though cisplatin can penetrate through the blood-tumor barrier albeit 
poorly. [24] Cisplatin and etoposide again were tested as combination agents in 56 
BCBM patients. 7 patients achieved a “complete” response, 14 achieved partial response, 
12 had no change, 16 continued to progress, and 8 patients were deemed as insufficient 
treatment or not assessed. An overall response rate of 38% was noted.[25] Cisplatin, 
doxorubicin, 5-fluorouracil, methotrexate regimens were given to 4 patients with BCBM. 
However, no overall survival improvement was noted, and patients experienced major 
toxicity. [26]  
Cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin were tried in 56 
BCBM patients. The authors reported no significant prolonging of intracranial metastases 
free interval, but progression free survival was prolonged. [27] 15 patients with BCBM 
were treated with cyclophosphamide and cisplatin in a Phase II trial. Of these 15, 6 
achieved partial response, defined as at least 50% reduction in tumor, and had no new 
lesions or progression. [28] In another Phase II trial, 25 patients with BCBM treated with 
cisplatin and vinorelbine alongside 30 Gy of fractionated radiation. This therapy resulted 
in complete response in 3 patients and partial response in 16 patients, for a total response 
rate of 76%. [29] The currently ongoing A-PLUS trial evaluates the BEEP (bevacizumab 
followed by etoposide and cisplatin) regimen alongside WBRT in BCBM patients. 
[NCT02185352] The BEEP combination was previously featured in a Taiwanese trial of 
BCBM, though no results are posted. [NCT01281696] Similarly, in a Phase II trial, 35 
patients with BCBM were pretreated with bevacizumab and then given cisplatin and 
etoposide, with a 77% response rate.[30] Cisplatin is also being evaluated alongside 
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veliparib in the treatment of BRCA-mutated breast cancer and its associated brain 
metastasis. [NCT02595905]  
 Paclitaxel is known to have low brain and CSF concentrations. In 152 metastatic 
breast cancer patients with brain metastases, 78 patients responded to paclitaxel, while 6 
developed CNS progression. The brain was thought to be sanctuary site for BCBM. [31] 
Of 4 BCBM patients given concomitant paclitaxel and bevacizumab, 3 showed partial 
response and 1 showed complete response, with no extra progression. [32] Five BCBM 
patients receiving similar bevacizumab and paclitaxel treatment showed partial response 
(2 patients), stable disease (2 patients), and progression (1 patient). [33] 
 Temozolomide as a single agent has been studied in a Phase II trial of BCBM, 
though no results have been posted. [NCT00831545] In combination with vinorelbine, 
temozolomide was used in 6 BCBM patients to achieve only a minor response, which 
then progressed. [34] It was then again used in a Phase II trial of 11 BCBM patients. One 
had a minor response, while the others were grouped together in stable or progressing 
disease. [35] 
 Though irinotecan is not typically used to treat brain metastases, it has found 
utility in combination therapy. It was studied in combination with temozolomide in 
BCBM [NCT00617539], but results of the study are not posted. Irinotecan was combined 
with iniparib and showed clinical benefit in 27% of patients. [36] Similarly, eribulin is 
used as salvage therapy in the treatment of BCBM; as such only case reports or case 
series of eribulin efficacy in this setting exist. In one patient, eribulin was fifth-line 
initiated. One month later, brain metastases reduced. [37] In three patients with BCBM 
(one of each subtype), eribulin was found to be beneficial in heavily treated n=3 patients. 
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[38] With concurrent WBRT, eribulin showed regression of one HER2- and one HER2+ 
BM. [39] Based on positive outcomes, eribulin is being evaluated in a Phase II trial of 
women with BCBM. [NCT02581839] 
2.1.4 Targeted Breast Cancer Brain Metastases Chemotherapy 
Luminal A, Luminal B, and HER2+ BCBM can be treated with targeted 
chemotherapy, while the triple negative subtype by definition cannot. The Luminal 
subtypes are often treated with selective ER modulators (SERM) such as tamoxifen, 
aromatase inhibitors such as anastrozole, or ER degraders such as fulvestrant, but there is 
no specific FDA-approved chemotherapeutic agent or regimen. [40, 41] Temozolomide 
has been studied in combination with WBRT, irinotecan, and capecitabine in hormone 
positive BCBM. [40] Upcoming therapy for hormone positive BCBM includes cyclin-
dependent kinase 4/6 inhibitors such as abemaciclib, palbociclib [NCT02774681], and 
ribociclib; PI3K inhibitors such as buparlisib and pictilisib; and tyrosine kinase inhibitors 
such as cabozatinib. Due to the favorable prognosis of Luminal BCBM, focus has shifted 
to trials and chemotherapy involving the HER2+ receptor and downstream pathways, 
which is associated with aggressive tumors and a large percentage of BCBM. 
The discovery of the HER2 receptor led to the creation of the targeted monoclonal 
antibody Herceptin (trastuzumab). FDA-approved in 1998, trastuzumab displayed a 
modest increase in overall survival. [42] Unfortunately, it was discovered that 
approximately 70% of patients experienced disease progression or developed metastasis 
within a year of starting trastuzumab. [42] Due to its size, trastuzumab is unable to 
penetrate the BBB or BTB in adequate concentrations, leading to the formation and 
inadequate control of intracranial metastases. [4, 43] The efficacy of the trastuzumab and 
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emtansine conjugate in HER2+ BCBM is discussed in the following immunotherapy 
section. 
The second HER2 antibody, pertuzumab, is often given in combination with 
trastuzumab to treat metastatic breast cancer. Case reports [44] and a subset of patients in 
the Phase III CLEOPATRA trial show that the combination of pertuzumab, trastuzumab, 
and docetaxel delays the onset of CNS metastases—but not the incidence of formation—
compared to placebo, trastuzumab, and docetaxel therapy. [45] The third HER2 antibody 
margetuximab is currently in Phase III trials in combination with chemotherapy for the 
treatment of metastatic breast cancer. [46] 
Tykerb (lapatinib) is a small-molecule tyrosine kinase inhibitor acting 
intracellularly to inhibit the HER2 signaling pathway. Unfortunately, much like 
trastuzumab, it does not display much efficacy in treating HER2 BCBM as monotherapy. 
A Phase II trial of 242 patients revealed an objective response of just 6%, with 21% 
patients displaying a ≥20% volumetric lesion reduction. [47] Lapatinib is being explored 
in combination with other medications, most frequently capecitabine, and treatment 
modalities. A Phase II study in combined lapatinib and capecitabine therapy, where 29 of 
44 patients achieved a partial response, though progression occurred in almost all patients 
and required brain radiation. [48] Many other trials have shown efficacy of lapatinib and 
capecitabine. [47, 49] Lapatinib was unfortunately shown not to work in combination 
with topotecan therapy. [50] Recently, a Phase II trial is examining the effects of 




Neratinib, another tyrosine kinase inhibitor of the HER2 pathway, was shown to 
be effective in treating HER2+ BCBM in combination with paclitaxel. [51] Another 
clinical trial combined neratinib and capecitabine to treat HER2 BCBM, with a 63% 12-
month survival rate in 39 patients, though 6 patients had to discontinue due to 
toxicity.[52] [NCT01494662] In contrast, the HER2+ tyrosine kinase inhibitor afatinib 
was compared against monotherapy, combined therapy with vinorelbine, and physician’s 
choice therapy in HER2+ BCBM. No improved efficacy in afatanib-containing regimens 
compared to physician’s choice was noted. [53] 
2.1.5 Immunotherapy for Breast Cancer Brain Metastases 
The first immunotherapy to treat cancer was interleukin-2 (IL-2) in advanced 
melanoma and renal cell carcinoma. [54] In consideration of brain metastases, IL-2 had a 
18.5% clinical response in previously treated patients and a 5.6% response rate in 
treatment-naïve patients, with only 2 of 36 naïve patients demonstrating objective 
intracranial disease regression. [54]  IL-2 was followed by Yervoy (ipilimumab), a 
cytotoxic T-lymphocyte associated protein (CTLA)-4 (CD152) antibody inhibitor. In a 
Phase II trial, ipilimumab showed control of brain lesions in 14 of 72 metastatic 
melanoma patients. [55] Subsequent trials show marginal or equivocal results with 
combination therapy or surgical treatment. [56] 
Great interest has been placed on immunotherapy in treating brain metastases. 
This is because unlike conventional chemotherapy, immunotherapy does not act directly 
on tumor cells: rather, T-cell activation leads to clinical responses seen. [57] As expected, 
initial trials of immunotherapy specifically precluded the enrollment of patients with 
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brain metastases without specific prerequisites. [58] Immunotherapy is now being 
explored in the treatment of brain metastases from various cancer types. 
The expression of PD-L1 on BCBM tumor surfaces is highly variable. A series of 
252 brain metastases from melanoma, breast, renal, colorectal, and non-small cell, and 
small-cell lung cancer were analyzed for expression of PD-L1 with less than 10% 
showing expression. [59] In contrast, another study of 84 patients with matching primary 
breast tumor and brain metastases found 53% PD-L1 expression on brain metastases. [60] 
Interest in immunotherapy to treat breast cancer lies especially in the treatment of TNBC, 
as no targets naturally exist against this subtype. [10, 61] Additionally, it has been shown 
that TNBC may harbor elevated levels of PD-L1. [10] 
Nivolumab, an antibody against PD-1, was shown to have a modest response 
(22%) in a small 50-patient trial of TNBC patients. [62] Nivolumab is currently involved 
in a Phase II trial of metastatic TNBC brain metastases in asymptomatic and steroid-free 
patients. [NCT02499367] It is also involved in combination therapy for metastatic TNBC 
[NCT02499367], but is not being trialed specifically for brain metastases.  
Pembrolizumab, another PD-1 inhibitor, was given to 111 patients with TNBC in 
the KEYNOTE-012 trial. Of note, 58.6% of patients had positive expression of PD-L1. 
Of 27 evaluatable patients, the overall response rate was 18.5%. [63] The KEYNOTE-
086 trial of pembrolizumab monotherapy in treating metastatic TNBC showed its 
efficacy, but again excluded any patients with brain metastases. [NCT02447003] 
Pembrolizumab is now being explored in the treatment of BCBM with the caveat of 
excluding HER2+ brain metastases. [NCT02886585]. In a newly launched trial, the 
combination of activated T-cells and pembrolizumab to treat metastatic breast cancer 
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allows for previously treated, stable HER2+ BCBM patients be enrolled. 
[NCT03272334] 
The PD-L1 inhibitor atezolizumab showed variable efficacy in the Phase I 
TONIC trial of 112 metastatic TNBC patients. While only 10% of patients responded to 
atezolizumab, the median duration response was 21 months, and all patients who 
responded were alive after 2 years compared to just 11% survival in non-responders after 
2 years. [64] Another PD-L1 inhibitor avelumab showed effectiveness in the JAVELIN 
trial featuring TNBC patients, but did not look at patients with brain metastases. [65] 
Durvalumab is another PD-L1 inhibitor being explored for metastatic TNBC. [61] 
Pembrolizumab and atezolizumab are also being explored for the treatment of hormone 
receptor positive breast cancer. [66] 
The conjugation of trastuzumab and emtansine (T-DM1) allows for specific 
targeting and selective cytotoxicity against HER2+ cancer cells. The discovery of T-DM1 
efficacy in HER2+ BCBM was surprising, as it is even larger than the parent antibody. In 
early 2015, the phase III EMILIA trial compared T-DM1 against capecitabine and 
lapatinib in the treatment of HER2+ BCBM. Overall survival was 26.8 months in the T-
DM1 group and 12.9 months in the conventional treatment group. [67] Later that year, a 
case series of 10 patients with HER2+ breast cancer and brain metastases who received 
T-DM1 showed 3 patients with partial remissions and stable disease for 6 months in 2 
patients, with a median survival of more than 8.5 months. [68] Multiple case series have 
reported reductions in intracranial lesion size with T-DM1 therapy in HER2+ BCBM. 
[69, 70] It was postulated that the antibody conjugate was better able to cross the 
disrupted BBB seen in tumor environments, though this remains highly controversial. 
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One retrospective study suggests that T-DM1 therapy, much like trastuzumab therapy, 
may lead to formation of brain metastases despite adequate extracranial disease control. 
[71] T-DM1 was tested in the BIRTH trial, and is currently involved in the KIARA trial, 
both specifically for HER2+ BCBM. [NCT02135159, NCT03203616] It is being 
investigated in combination with tucatinib (ONT-380) for the treatment of HER2+ 
BCBM. [NCT01983501] 
The discovery of PD-1/PD-L1 and efficacy of T-DM1 has renewed interest in 
exploring the microenvironment of BCBM.  
2.2 Lung Cancer Epidemiology  
In the United States, lung cancer is the second most common cause of cancer in 
men and women, but is the most common cause of cancer death.[72] It is estimated that 
more than 200,000 new cases of lung cancer will be diagnosed and more than 150,000 
deaths from lung cancer will occur—more than 25% of all cancer deaths. [72] 
Worldwide, it is the most common cause of cancer and of cancer death. The median age 
of diagnosis is at 70, with median age of death at 72. [73] The incidence of lung cancer 
has sharply declined for men and slowly declined for women reflecting new trends in 
tobacco use. Despite incidence decreasing due to initiatives to reduce tobacco use, there 
is approximately a 20-year lag in mortality improvement: the 5-year survival for lung 
cancer is only 18%. This is because more than half of lung cancer will be metastatic on 
diagnosis due to the lack of a ubiquitous non-invasive screening tool. [72] Screening for 
lung cancer is limited to current or former smokers with at least a 30-pack year history. 
Prior to the 1980s, lung cancer was primarily a disease of men. As women began 
to consume tobacco, the “gender gap” of incidence and death rates due to lung cancer 
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between men and women have narrowed. [74] Women are potentially more susceptible to 
developing lung cancer while men have a higher mortality rate. [75] This may be due to 
the estrogen receptor ß, which when activated causes proliferation and contributes 
significantly to mortality, or other genetic differences allowing for DNA damage to have 
greater impact than in males. [74] Smoking history remains the most important risk factor 
for developing lung cancer, linked to more than 80% of lung cancer cases and deaths. 
[74] Approximately 21% of Americans (46 million people) consume tobacco products. 
[73] Smoking rates and linked lung cancer rates have been declining in the United States, 
but rising sharply in Asian countries which huge increases in smoking rates. [73] 
With smoking such a strong link to smoking to the point of being a causative 
factor, it is paradoxical that up to 25% of lung cancer occur in “never-smokers”, which 
are defined as people who have smoked fewer than 100 cigarettes in their lifetime. [73] 
This finding is geographical, as a Japanese study showed that the percentage of never-
smokers with lung cancer increased from 16% to 33% in a 30-year period, while in the 
same period only 20% of lung cancer were associated with never-smokers. [73] Though 
smoking is postulated as a broad, causative factor for lung cancer, only specific subtypes 
of lung cancer are linked with smoking exposure. 
2.2.1 Lung Cancer Subtypes 
Lung cancer is split into two broad classifications: small-cell lung cancer (SCLC) 
and non-small cell lung cancer (NSCLC). NSCLC is responsible for more than 80% of 
lung cancer diagnosis. [76] Within NSCLC, the three most common subtypes are 
adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. These cancers form 
approximately 39%, 20% and 3% of all lung cancers, respectively. [73, 77] Smoking is 
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strongly linked with SCLC and squamous cell carcinoma. Though adenocarcinoma is 
more closely linked with never-smokers, the incidence of adenocarcinoma in patients 
who smoke is becoming more common. [73]  
SCLC is a highly aggressive tumor, possessing rapid growth, neuroendocrine 
activity creating paraneoplastic syndromes, high vascularity, and rapid lethality due to 
early metastatic dissemination. [78] Though SCLC is highly responsive to both radiation 
and chemotherapeutic treatment, resistance rapidly and inevitably occurs, leading to 
untreatable relapses. [78] Nearly ubiquitous mutations in TP53 renders genomic 
instability and the MYC oncogene promotes rapid growth. [78] Since SCLC typically 
does not possess any mutations explicitly for drug targeting, systemic chemotherapy is 
given by default. Due to the metastatic nature of SCLC, resection is generally not 
performed, in contrast to NSCLC. Patients with non-Stage IV NSCLC typically have 
tumor resection via video-assisted thorascopic surgery (VATS) if surgery is tolerable, 
followed by radiation and/or chemotherapy. [77]  
Within NSCLC, adenocarcinoma possesses several mutations that influence 
prognosis and survival. These derangements are checked for on initial diagnosis of 
advanced disease. [79] Mutations in the KRAS oncogene occurs in up to 25% of 
adenocarcinoma and is associated with smoking history. Presence of KRAS mutations 
increases tumor aggressiveness and disease relapse, along with reduced response or 
increased resistance to chemotherapy. [80] Interestingly, KRAS mutations have an 
inconsistent effect on prognosis, as trials have reported that both wild type and mutated 
KRAS have similar outcomes on chemotherapy or that mutants have shorter progression-
free and overall survival. [81] Mutations in KRAS may be a poor prognosis marker 
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specifically in women with stage I NSCLC and Asian patients, and mutations in codon 13 
confers resistance to chemotherapy when compared to codon 12 mutations. [81] KRAS 
acts downstream from the EGFR pathway, thus mutations in the KRAS oncogene lead to 
suboptimal therapeutic response or outright resistance to EGFR inhibitors. [82]   
Mutations of EGFR occur in approximately 20% of adenocarcinoma, which 
allows the evasion of programmed cell death, enhanced migration, and metastases 
facilitation. [83] Found in women, never-smokers and Asian patients, EGFR mutations 
however confer a positive prognosis, as the receptor is susceptible to inhibition by 
competitive tyrosine kinases. [83, 84] The most common EGFR mutations occur on 
exons 18-21, with exon 19 deletion (L8658R) being the most common (60%) and a point 
mutation on exon 20 being second-most common. [83, 85] It is purported that the 
mutations on exons 19 and 21 allow for targeting of tyrosine kinase inhibitors. [86] 
Insertions on exon 20 may lead to tyrosine kinase inhibitor resistance, and the T790M 
mutation is found in more than half of treated tumors. [83] While EGFR mutation occur 
early in disease, amplification occurs late in disease and is associated with metastases. 
[87] Inhibitors to overcome this mutation have been developed, which in turn have 
caused a C797 mutation to develop within the EGFR ATP-binding site. Unfortunately, 
targeted inhibitors do not improve survival without an EGFR mutation, so systemic 
chemotherapy must be given to patients with wild-type EGFR. [85]  
The discovery of anaplastic lymphoma kinase (ALK) and echinoderm 
microtubule-associated protein-like 4 (EML4) rearrangements which occur in 7% of 
adenocarcinoma in 2007 was monumental and drove tyrosine kinase inhibitor 
development. [88] The t(2;5) chromosomal translocation allows constitutive ALK 
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activity. [85] ALK-EML4 mutations are found in never-smokers and younger patients, 
similar to EGFR mutations, though mutually exclusive and distant from both and KRAS 
mutations. [89] Of 22 potential translocation variants, three major variants of ALK fusion 
are found clinically. Variant 1 features a E13;A20 exon fusion (33% of total ALK 
mutations), variant 3 has a E6a/b;A20 fusion (29%), and variant 2 possesses a E20;A20 
fusion (9%). [88] One small trial of 54 patients discovered that possession of the 3a/b 
ALK variant was a source of inhibitor resistance, but other trials report no correlation of 
ALK variance type on survival. [90, 91] Possession of an ALK translocation or mutation is 
associated with a poor prognosis and relapse or resistance to drugs within the first year of 
treatment. [92] 
Approximately 2% of lung cancer have ROS-1 fusion mutations. Much like ALK-
EML4 translocation mutations, ROS-1 mutations are associated with younger age and 
never-smokers. [93] Unlike the ALK-EML4 fusion protein, ROS-1 fusion protein 
mechanisms are unknown, but often feeds into common tyrosine kinase-signaling 
pathways. [94] Since it is so uncommon, ROS-1 testing is often performed only after 
EGFR and ALK results are negative. [94] The oncogene initially became an object of 
interest when it was discovered it was concomitantly inhibited by the first ALK inhibitor 
crizotinib, which subsequently gained FDA-approval to treat ROS-1 rearrangement 
NSCLC. [94] ALK and ROS-1 are so similar that more than 75% of amino acids are 
similar within the respective ATP-binding sites, which may explain why crizotinib is so 
effective in treating ROS-1 mutated NSCLC. [95] Newer ALK inhibitors such as ceritinib, 
lorlatinib, and entrectinib also inhibit ROS-1, presumably due to the homology. [96] 
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The expression of PD-L1 in NSCLC has been a subject of debate since variable 
expression exists not only between patients, but within tumor samples across time as 
treatment occur. A study of 95 patients showed that PD-L1 expression might increase 
when treated with EGFR inhibitors, thus enhancing the effects of PD-1/PD-L1 therapy. 
[97] Another trial of four patients showed that PD-L1 expression changed after 
chemotherapy and inhibitor treatment. [98] Though the presence of high levels of PD-L1 
is a poor prognosis indicator, especially in NSCLC, the presence allows for treatment 
with PD-1/PD-L1 inhibitors, which have revolutionized treatment for many cancer types. 
[99, 100] As the check-and-balance process of the immune system is impaired to allow 
hyperactivity, PD-1/PD-L1 inhibitors create significant burdensome and severe toxicity. 
[101] Despite these drawbacks, inhibitors are becoming a frontline therapy for the 
treatment of NSCLC and many solid tumors. 
Within the scope of brain metastases, EGFR mutations and ALK or ROS-1 
translocations allow targeting via tyrosine kinase inhibitors. First-generation inhibitors 
poorly penetrate the blood-brain or blood-tumor barrier and cause relapse within a year. 
[102] Subsequent generations are more effective and are being developed with the intent 
to treat brain metastases. [103] 
2.2.2 Lung Cancer Brain Metastasis 
More than 50% of all brain metastases are caused by lung cancer and the most 
common place for lung cancer to metastasize is the brain. [104] SCLC is the most likely 
lung cancer subtype to metastasize to the brain; at diagnosis approximately 20% of 
patients with SCLC will already have brain metastases, and approximately 80% will 
develop brain metastases within 2 years. [105, 106] In contrast, approximately 7% of 
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NSCLC patients will have brain metastases on presentation and up to 45% will develop 
brain metastases within 2 years. [105, 107, 108] Mutation status may play an important 
role in the development of lung cancer brain metastases (LCBM). It was found that 
mutant EGFR was more likely to develop multiple brain metastases than wild-type, and 
exon 19 deletions had smaller brain metastases. [109, 110] Approximately 30% of ALK 
NSCLC patients will develop brain metastases. [111] Conversely, ROS-1 mutations may 
cause lowered brain metastases rates. [111] Median survival of patients with LCBM at 
presentation is approximately 4 months, and with aggressive treatment lengthens to just 
over 12 months. [108, 112, 113] Patients who develop brain metastases later in disease 
tend to live longer than those at diagnosis, and receiving chemotherapy increases survival 
by approximately 2 months. [112] 
Much like BCBM, chemotherapy, surgery, and radiation are components in first-
line treatment of LCBM. Karnofsky performance status (KPS), age, number of 
intracranial metastases, control of primary cancer, and the presence of extracranial 
metastases are factors that predict clinical outcomes. [114] Female gender, age less than 
58, adenocarcinoma subtype, single brain lesions, and surgical resection are considered to 
be favorable prognostic factors. [115] Surgery is typically restricted to large and 
symptomatic metastases. In the Quartz trial, WBRT revealed no survival benefit in the 
context of LCBM. [116] Additionally, WBRT causes significant neurotoxicity and 
cognitive decline. SRS shows a better adverse effect profile, and when combined with 
WBRT, shows significant tumor control with lower rates of new intracranial lesions. 
[117] Chemotherapy is often given to control primary tumor, but due to the failure to 
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adequately cross the blood-brain and blood-tumor barriers, often results in sub-
therapeutic activities in treating LCBM.[108] 
2.2.3 Conventional Lung Cancer Brain Metastases Chemotherapy 
Brain metastases from both SCLC and NSCLC have a history of responsiveness 
to chemotherapy. SCLC brain metastases are more initially responsive and often have a 
complete response, followed by relapse. [118] Brain metastases from NSCLC that 
possess a mutation surprisingly have a favorable outcome and responsiveness to 
chemotherapy, perhaps due to the necessity of the oncogene to exert tumor activity. [119] 
The backbone of most non-targeted lung cancer therapy consists of cisplatin and another 
agent such as etoposide, topotecan, or pemetrexed. [108, 120, 121] Temozolomide is 
commonly added to treat brain lesions. Other drugs to treat LCBM include vincristine, 
cyclophosphamide, lomustine, and doxorubicin. [113] 
In the GFPC 07-01 Phase II trial, 43 NSCLC brain metastases patients were 
treated with cisplatin and pemetrexed every 3 weeks, in combination with WBRT. 
Survival was extended to 7.4 months, with the development of severe hematological 
toxicity in 17 patients. [122] Another similar trial with cisplatin, pemetrexed, and 
radiation extended survival to 12.6 months with combination therapy. [123] In a 
comparison of cisplatin and pemetrexed against temozolomide and pemetrexed, it was 
found that the same efficacy existed but pemetrexed and temozolomide had fewer 
adverse reactions, making the combination potentially more beneficial for NSCLC brain 
metastases. [124] Since pemetrexed achieves CSF concentrations similar to serum levels, 
it has been described as the “preferred” agent in platinum doublet chemotherapy. [125] 
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Bevacizumab has gained footing as a standard-of-care therapy option in the 
treatment of LCBM. Initial concern over bevacizumab administration in brain metastases 
due to the risk of intracranial hemorrhage was mitigated as two trials showed its safety in 
this setting. [126] In the French EOLE cohort study, bevacizumab alongside platinum-
doublet therapy showed similar survival in patients with or without brain metastases. 
[127]. In a case series of 4 NSCLC patients with a total of 60 brain metastases, 
bevacizumab was combined cisplatin and pemetrexed along with stereotactic 
radiosurgery, and was found to reduce the volume of tumors by an average of 75%. [128]  
More clinical trials have supported the use of bevacizumab and platinum-based 
chemotherapy in the treatment of NSCLC brain metastases. [128-133] Presence of brain 
metastases is advocated to no longer be a contraindication to bevacizumab use. [134] 
Temozolomide, FDA-approved for glioblastoma, has been explored for treating 
LCBM. Results are varied: temozolomide was not shown to have any efficacy in the 
Phase II EORTC 08965 study [135], and surprisingly not even in combination with 
radiation therapy shows efficacy. [136] In contrast, another Phase II trial showed stable 
disease in 10% of patients treated with temozolomide previously treated with WBRT and 
chemotherapy.[137] Two clinical trials involving temozolomide specifically for NSCLC 
brain metastases have been conducted, but no results are posted. [NCT00076856, 
NCT00034697] Currently, temozolomide does not play an active role in first-line therapy 
for LCBM.  
2.2.4 Targeted Lung Cancer Brain Metastases Chemotherapy 
Due to the presence of numerous genetic aberrations, targeted inhibitors are being 
explored for concomitant primary lung tumor tumor and accompanying brain metastases 
27 
 
treatment. Three major therapeutic targets exist: EGFR, ALK, and PD/PD-L1. The latter 
will be explored in the immunotherapy subsection. Beginning with the first-generation 
EGFR inhibitors in 2004, gefitinib and erlotinib were the first step in personalized 
medication for NSCLC. Due to the high presence of brain metastases in NSCLC patients, 
gefitinib and erlotinib were tested for efficacy in this setting shortly after discovery.  
Gefitinib is the first of the first-generation EGFR inhibitors approved for NSCLC 
patients. It has been shown to penetrate through the BBB, though the extent is 
controversial. Plasma-to-CSF ratios is reported as approximately 20% [138], with a 
strong dose correlation. [139] Human pharmacokinetics apparently vastly differ from 
primate kinetic data, which show virtually no gefitinib uptake into brain parenchyma. 
[138] Multiple small trials evaluated gefitinib in EGFR-mutated LCBM, both concluded 
gefitinib provides enhanced survival. [140-142] Gefitinib has also shown efficacy when 
combined with WBRT. [139] One case report shows gefitinib treating LCBM refractory 
to erlotinib therapy, which is discussed next. [143] 
Erlotinib has been shown to penetrate the BBB ease, achieving concentrations in 
the CSF required to reduce intracranial tumor burden. [144] PET/CT scans show erlotinib 
accumulating preferentially in brain lesions compared to normal brain parenchyma. [145] 
A 69-patient trial showed erlotinib achieving an 82.4% response rate in patients with 
EGFR mutant LCBM. [146] In one instance, erlotinib was able to control a brain 
metastases refractory to another EGFR inhibitor afatinib, a second generation EGFR 
inhibitor, discussed next. [147] 
Differences among the first generation EGFR inhibitors exist. A comparison of 
119 gefitinib and 13 erlotinib patients with NSCLC brain metastases showed erlotinib 
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having both better intracranial disease control and lower recurrence rate. [148] 
Unfortunately, both gefitinib and erlotinib require EGFR mutations in order to be active, 
and Phase II trials demonstrated no beneficial effects when these agents were given in 
EGFR wildtype LCBM patients. [149, 150] Another trial confirmed these findings in 
combination with WBRT. [151] The role of first-generation EGFR inhibitors and 
radiation therapy is not clear-cut. In instances, erlotinib has been shown to be synergistic 
with WBRT [152], while in other cases there was no significant improvement in 
combination. [153]  
Afatinib, a member of the second-generation EGFR inhibitors, was shown to be 
effective in treating EGFR-mutated LCBM during the LUX-Lung 3 and LUX-Lung 6 
trials compared to cisplatin-pemetrexed or cisplatin-gemcitabine therapy, respectively. 
[154] Patients in these trials respondent to afatinib had an exon 19 deletion and L858R 
point mutation. This finding was peculiar, as preclinical work suggested afatinib is a 
substrate for drug efflux pumps such as P-glycoprotein and BCRP, restricting 
accumulation into the brain. [155] On the other hand, a LCBM model using PC-9 EGFR 
mutant cells showed penetration of the BBB and a reduction in tumor burden. [156] The 
discordance of preclinical and clinical finding has led to afatinib being involved in a 
pharmacokinetic study to determine distribution and dose-responses in LCBM. 
[NCT02423525] Dacomitinib, another member of the second-generation irreversible 
EGFR inhibitors, was being explored for brain metastases, though the study is now 
terminated. [NCT02047747]  
Despite these advances in targeted therapy and increasing BBB/BTB penetration, 
CNS progression occurs in approximately 50% of patients within 3 years of therapy 
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initiation. [157] Due to the high incidence of lung cancer patients developing brain 
metastases, focus shifted on creating targeted inhibitors to treat LCBM. 
Osimertinib is currently the only FDA-approved member of the third generation 
EGFR-inhibitors. While it also targets exon 19 deletions and L858R mutations, it is 
specifically used when first- or second-generation EGFR inhibitors have failed and there 
is a concomitant T790M mutation. [158] The prevalence and significance of the mutation 
is discussed in the subtype section, though one study has noted the presence of T790M 
mutations in brain metastases is lower than that of primary lung disease. [159] In the 
AURA (extension) and AURA2 trial, 50 patients with asymptomatic brain metastases 
were treated with osimertinib. 27 of 50 showed overall improvement and 6 of 50 showed 
complete CNS response. [160] In the Phase III AURA3 trial, osimertinib was superior to 
chemotherapy in treating T790M LCBM. [161] The AURA17 trial similarly showed 
osimertinib leading to complete response in 10 patients and partial response in 15 patients 
with T790M LCBM. [NCT02442349] The upcoming Phase II APPLE trial will compare 
the effect of osimertinib and gefinitib on LCBM. [162] The upcoming third-generation 
AZD3759 is being trialed against osimertinib in the BLOOM study, which specifically 
focuses on LCBM efficacy. [163] [NCT02228369] 
ALK inhibitor discovery have outpaced that of EGFR inhibitors, perhaps due to 
their concomitant ROS-1 inhibition. Three generations of inhibitors exist, and much like 
EGFR inhibitors, increases in generation are correlated with enhanced BBB/BTB 
penetration for intracranial efficacy.[164]  
The first agent FDA-approved for treating ALK-rearranged NSCLC was 
crizotinib. Though good at controlling peripheral disease, a case report showed CSF 
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accumulation and subsequent CNS disease progression. [165] Pooled data from the 
PROFILE 1005 and PROFILE 1007 trials showed that CNS progression occurred in 70% 
of patients treated with crizotinib. [166] Crizotinib does initially control intracranial 
disease, but progression is inevitable, with most patients developing resistance within 2 
years. [167] It is postulated that the inefficacy in LCBM is due to efflux pump activity, as 
crizotinib is a substrate for ABCB1/ABCG2. [168] Similar efflux pumps restrict full 
ceritinib penetration into the brain, but apparently not its efficacy in LCBM. [169] 
Ceritinib, a member of the second-generation ALK inhibitors, is used in patients 
who have progressed or become resistant on crizotinib therapy. Results of the ASCEND-
1 trial showed ceritinib controlled intracranial disease in 15 of 19 treatment-naïve LCBM 
patients and 49 of 75 pretreated LCBM patients. [170] This led to the Phase II ASCEND-
2 trial which confirmed the ASCEND-1 findings of ceritinib use in both crizotinib-
pretreated and chemotherapy-naïve patients with ALK-mutated LCBM. [171, 172] The 
recently-conducted ASCEND-5 trial compared single-agent ceritinib against 
chemotherapy in patients who had progressed on both crizotinib and platinum-based 
chemotherapy. Preliminary results show ceritinib improving overall survival. [173]  
The other second-generation ALK inhibitor, alectinib, is a poor substrate for efflux 
pumps such as ABCB1 and ABCG2. [174] In a Phase II study, 84 crizotinib-refractory 
LCBM patients were treated with alectinib. 83% of CNS disease rate was controlled for a 
median of 10.3 months, though at 12 months 24.8% had CNS progression. [175] Two 
recent trials have shown alectinib’s efficacy in LCBM. The Phase III ALEX trial 
compared alectinib and crizotinib with a radiation modifier, showing that alectinib 
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achieves response with or without radiation [176], and the ALUR trial showed alectinib 
superiority over platinum-doublet therapy in treating brain metastases. [177] 
Brigatinib, a combined third-generation ALK and EGFR inhibitor, was approved 
in April 2017 for the treatment of metastatic NSCLC, specifically as second-line therapy 
for ALK-positive NSCLC. In the first of two Phase II trials, 31 patients (35%) had 
complete resolution of brain lesions, while in the second study, a combined 25% had 
complete resolution of brain lesions. [178, 179] 
Lorlatinib, a combined ALK and ROS-1 inhibitor, is undergoing clinical phase 
trials for the treatment of ALK-positive NSCLC. It is said that lorlatinib was designed to 
primarily permeate through the BTB and treat LCBM. [180] 11C-lorlatinib was given to 
non-human primates and PET imaging revealed enhanced distribution to the brain, liver, 
and spleen. [180]Similarly, nude mice bearing NCI-H3122 subcutaneous xenografts were 
given the radioactive drug and showed enhanced uptake. [180] In a Phase II trial of 
patients with ALK-LCBM, 7 of 23 patients had a complete response on the drug, while 4 
had a partial response. [181] 
Entrectinib, an ALK, ROS-1, and Trk A-C inhibitor, has shown to be effective in 
NTRK-positive LCBM. Similar to lorlatinib, it is designed to cross the BBB/BTB. [182] 
Two possibilities for initial response followed by relapse is the presence of the 
BBB and BTB, which create a sub-therapeutic environment for resistance to form. This is 
the case for all chemotherapy acting directly on receptors or targets in tumor cells, but as 
discussed next, not a possibility for immunotherapy. 
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2.2.5 Immunotherapy for Lung Cancer Brain Metastases 
Much like breast cancer, the discovery of PD-1 and PD-L1 checkpoint inhibitors 
has propelled agents to first-line therapy in the treatment of lung cancer. It was found that 
NSCLC LCBM has higher expression of PD-L1 compared to the primary lung tumor. 
[58, 163] Further, PD-L1 expression in the context of NSCLC is associated with poor 
prognosis. [183] PD-1 and PD-L1 inhibitors are typically antibodies, such as nivolumab, 
pembrolizumab, and atezolizumab. All three are FDA-approved to treat metastatic 
NSCLC after progression on platinum-based therapy. [184] Pembrolizumab can be used 
as first-line therapy in NSCLC patients without EGFR or ALK mutations, though if these 
mutations are present, all three agents are indicated if patients progress despite targeted 
therapy.  
Since EGFR inhibitors upregulate the PD-L1 expression on tumor cells, trials 
initially recruited patients who were refractory to these agents. One study has shown that 
patients with wild-type EGFR show better improvement in overall survival compared to 
patients with EGFR mutants when given checkpoint inhibitors. [185] The role of PD-
1/PD-L1 inhibitors in the presence of EGFR mutation has been a subject of investigation. 
[186-190] Preliminary reports combined targeted agents and checkpoint inhibitors, 
revealing encouraging results but early termination due to significant side effects. [191, 
192] Clinical trials are ongoing combining the two therapies. [NCT02039674, 
NCT02364609, NCT02013219, NCT02574078, NCT02393625, NCT02584634, 
NCT02898116, NCT02323126, NCT02454933, NCT01998126] 
Interestingly, KRAS mutations are not associated with increases of tumor PD-L1 
expression, and ALK oncogene expression have variable effects. [184, 193] To date, no 
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published data specifically combine ALK-inhibitors and PD-1/PD-L1 therapy in the 
context of metastatic NSCLC or LCBM, but trials are underway. [NCT02511184, 
NCT01998126] 
Pembrolizumab, in the KEYNOTE-024 trial, used information from KEYNOTE-
001 and KEYNOTE-010 to prove that it was superior to physician’s choice of platinum-
based doublet therapy in the treatment of NSCLC. Enrollment included patients who had 
no EGFR mutations or ALK translocations. [194] In a small Phase II trial with 18 NSCLC 
patients with brain metastases, pembrolizumab achieved a response rate in 6 patients 
(33%) that was sustained in all but one patient.  [195] It is being explored in the treatment 
of brain metastases, but excludes SCLC and NSCLC with either EGFR mutations or ALK 
translocations. [NCT02886585]  
Nivolumab showed an improvement in 2 of 12 patients with untreated NSCLC 
CNS metastases in a portion of the CheckMate 012 trial. [196] In five patients with 
LCBM, one patient achieved a complete and partial response each. [197] A retrospective 
analysis of 48 LCBM patients revealed no response with nivolumab monotherapy, but 
did show a response with radiation therapy prior to nivolumab initiation. [196] These data 
lead nivolumab to be combined with stereotactic radiosurgery in an active Phase II trial 
of LCBM patients. [NCT02978404] 
In the Phase III PACIFIC trial, durvalumab showed efficacy in patients with 
NSCLC. In this trial, new incidence of LCBM occurred in 11% in placebo-treated 
patients compared to 5.5% treated with durvalumab. [198] Capitalizing on this success, 




Much like the other two checkpoint inhibitors, atezolizumab too has shown 
efficacy in LCBM. In a subset of OAK patients, atezolizumab was compared with 
docetaxel on survival from, and time to develop LCBM. Atezolizumab improved survival 
by nearly 8 months compared to docetaxel, with a lower risk of developing new lesions. 
[199] Avelumab, an upcoming PD-L1 inhibitor, was shown to be effective in the 
JAVELIN trial for NSCLC, but did not include patients with brain metastases. [200] The 
upcoming JAVELIN-100 trial includes asymptomatic LCBM patients with certain 
criteria. [NCT02576574]  
Other forms of therapy to stimulate the immune system include adoptive cell 
transfer of tumor-infiltrating lymphocytes, BCG vaccine, and antigen-specific cancer 
vaccines. These have not been shown to be effective in the treatment of NSCLC or their 
brain metastases. [201] 
2.3 Glioblastoma Epidemiology 
While 80% of all intracranial tumors are from metastases, the primary malignant 
brain tumor glioblastoma comprises approximately ~16%.  [202] Glioblastomas primarily 
occur in the frontal or temporal regions of the cortex, though instances of tumors in the 
spinal cord, cerebellum, and brain stem have been noted. [202] Though highly invasive 
through brain parenchyma, they are restricted to these areas of the central nervous system 
and do not metastasize. [203] Much like other intracranial tumors, glioblastoma are 
highly heterogeneous and feature mutations in chromosomes leading to tumor suppressor 
gene loss and/or amplification and expression of oncogenes. [203] The median age of 




The risk factors for developing glioblastoma are not definitively recognized, 
however ionizing radiation has been highly associated with the delayed development of 
gliomas. [202] Cellular mutations of p53, EGFR, PTEN, PI3K, RAS, and Rb have been 
found in glioblastoma, along with isocitrate dehydrogenase 1 mutations in secondary 
glioblastomas. [202, 204] Interestingly, the enzyme O-6-methylguanine-DNA 
methyltransferase (MGMT) is a predictive factor for survival: patients with MGMT-
methylated tumors survive approximately twice as long as non-MGMT-methylated 
tumors (22-26 months vs. 12-15 months, respectively). [204] The MGMT enzyme is 
associated with better outcomes from medication therapy. [202, 203] 
Current therapy for glioblastoma includes surgical resection followed by adjuvant 
radiation therapy, often combined with chemotherapy. Aggressive surgical resection, 
especially with greater extent around margins, is associated with better outcomes. The 
size (>5 cm) and location of tumors (brainstem and diencephalon) are associated with 
poorer outcomes. [202] After healing from the surgery, radiation and chemotherapy are 
next. The typical radiation schedule is 60 Gy divided in 30 fractions, which is a lower 
per-dose fraction than other schedules but gives a higher total dose overall. [203] The 
next section talks about two FDA-approved non-specific chemotherapeutic agents for 
glioblastoma; no targeted agents exist. 
2.3.1 Glioblastoma Chemotherapy 
Two DNA-alkylating agents, temozolomide and carmustine, are FDA-approved 
for use in treating glioblastoma. [203] Temozolomide is orally administered 
concomitantly with radiation therapy, acting as both a cytotoxic agent and radiosensitizer. 
[205] It was shown that the MGMT may mediate this radiosensitivity. [205] This is 
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because MGMT encodes a DNA-repair enzyme; methylated MGMT inhibits this enzyme 
from being expressed and thus temozolomide activity is unimpaired. [202] 
Temozolomide as monotherapy improves survival to 15 months from 12 months with 
radiation therapy alone, with the combination of drug and radiation leading to 27% 
survival at 2 years and 10% at 5 years vs. 11% and 2% for radiation, respectively. [202] 
Carmustine, administered as degradable wafers, are applied to the regions 
remaining after tumor excision. Though a Phase III trial showed survival benefit 
compared to placebo, carmustine toxicity and the ease of temozolomide administration 
precludes the wafers from use as first-line therapy to treat glioblastoma. [203]  
2.3.2 Immunotherapy for Glioblastoma  
Much like melanoma, IL-2 was one of the first immunotherapeutic agents trialed 
in the treatment of glioblastoma. In 9 GBM patients, IL-2 administration showing 
increases in survival periods ranging 7- to 17-months. [206] A vaccine against the 
EGFRvIII, which is displayed in 20-30% of glioblastoma, did not increase survival in 
patients with newly diagnosed glioblastoma in combination with temozolomide or in 
comparison with temozolomide monotherapy. [207] 
Checkpoint inhibition is said to “revolutionize” treatment of solid tumors such as 
melanoma, non-small cell lung cancer, breast cancer, cancers which make up the top 80-
85% of brain metastases. In glioblastoma, the Phase III CheckMate-143 trial compared 
nivolumab to standard-of-care bevacizumab. No improvement in overall survival was 
noted. [NCT02017717] Despite this finding, nivolumab is being compared to 
temozolomide (each in combination with radiation therapy) [NCT02617589] and also in 
combination with temozolomide and radiation therapy against placebo. [NCT02667587] 
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Pembrolizumab was tested in combination with bevacizumab for newly-diagnosed 
glioblastoma [NCT02337491], and with MRI-guided laser ablation in recurrent 
glioblastoma [NCT02311582]. Durvalumab is being tested in combination with radiation 
therapy and bevacizumab [NCT02336165].  
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PHARMACOKINETICS OF LUCIFERIN IN PRECLINICAL BRAIN 
METASTASES AND PRIMARY BRAIN TUMOR MODELS 
3.1 Introduction 
Brain tumors are associated with significant mortality and morbidity, with 
patients succumbing to the tumors within two years [1]. Approximately 10-20% of 
intracranial lesions arise from cells of the central nervous system (CNS), such as glial 
cells which when mutated can result in the formation of glioblastoma [2, 3]. Of 
significance, and often overlooked in the preclinical literature is 80% of brain lesions 
start as a cancer in a distant tissue outside the CNS. The three dominant metastatic 
originating cancers are lung, breast and melanoma [4]. There have been a significant 
number of preclinical primary CNS and metastatic CNS models that have been recently 
developed. Accordingly, there is a substantial need to be able to longitudinally quantify 
tumor growth and response within the skull [5].  
Quantifying preclinical intracranial longitudinal tumor response to therapy can be 
difficult. Two common current modalities include magnetic resonance imaging (MRI) 
and computed-axial tomography (CT) [6]. While these imaging modalities are non-
invasive, they are often time-consuming and expensive. Direct cell-labeling with 
quantum dots or use of radionucleotides are similarly expensive and may cause 
significant toxicity [7, 8]. These imaging methods are being supplanted by the use of 
luciferase. Three types of luciferase exist: Gaussia, Renilla, and Firefly, the latter of 
which is used most commonly. Incorporation of the firefly luciferase (Fluc) enzyme into 
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cells allows for non-invasive, non-toxic visualization and quantification in both in-vitro 
and in-vivo settings [9].  
In bioluminescence, Fluc oxidizes its substrate D-luciferin in an ATP-dependent 
reaction to give off photons of light. These photons have an emission maximum (λmax) 
of approximately 560 nm, which exists close to far-red spectra and are easily 
distinguished against background light scatter for quantification accuracy [10]. As 
vertebral systems do not endogenously express Fluc and since ATP is required in the 
oxidation mechanism to produce photons, only living cells incorporated with Fluc will 
produce signal, with the amount of signal proportional to amount of photon-producing 
cells [10-12]. Neither Fluc incorporation nor D-luciferin create toxic effects in vertebrates 
or cells [13, 14]. This allows Fluc and D-luciferin to be a highly sensitive and reliable 
pairing for both real-time and longitudinal cellular proliferation, cellular migration, and 
tumor burden [10, 15]. This process is bioluminescence imaging (BLI). 
The rate of photon production from D-luciferin metabolism generally exhibit a 
gradual increase and decrease surrounding peak intensity [16]. It is suggested that this 
BLI peak that most accurately represents the extent of tumor burden [17]. Therefore, 
performing a D-luciferin pharmacokinetic profile maximizes measurement of tumor 
growth, chemotherapy response, and reproducibility in longitudinal studies. Each cell 
line, method of luciferin administration, and mode of tumor inoculation will produce 
different pharmacokinetic profiles [15, 18].  
Herein, we utilize intraperitoneal injections of D-luciferin and firefly luciferase 
pharmacokinetics to characterize BLI peak and minimal-error imaging times in three 
preclinical metastatic brain and one intracranial cancer models. These models include the 
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human HER2+ JIMT-1 and the triple negative MDA-MB-231 breast cancer lines, the 
EGFR-mutant PC-9 lung cancer line, and the intracranial U251 glioblastoma line. We 
observed an inverse relationship between peak photon production and length of optimal 
imaging time: while peak BLI signal is comparatively delayed in the breast-brain 
metastatic models, the optimal imaging duration is significantly longer than lung-brain or 
intracranial tumors (p < 0.05). Similarly, an inverse relationship between time to peak-
BLI and statistically error-free period was observed: the lung-brain metastatic and 
intracranial model had double the imaging window than the breast-brain metastatic 
models (p < 0.05). Large variability exists within the first 10 minutes of imaging in all 
models, and in intracranially injected models, this leaves sparse time for optimal 
quantification. Significant differences in area under the curve for total photon emission 
exists within groups of the in-vivo and in-vitro models (p < 0.05). In-vitro luciferin assays 
using the same cell lines produce consistent signal production at similar values to their in-
vivo peaks and greatly vary in their photon production and plateau region of optimal 
signal capture, which suggest that each cell line has different intrinsic luciferase kinetics. 
3.2 Methods and Materials 
Chemicals and reagents 
 A lentivirus containing Fluc with the hygromycin selection marker was purchased 
from Biosettia (GlowCell-16h). 10 μL of viral vector and 10 μL of polybrene (Santa 
Cruz, sc-134220) was added to each well in a 6-well plate of JIMT-1-Br or U251 at 70% 
confluence. Plates were spun at 1000 RPM for 60 minutes and placed in a 37C incubator 
overnight. The following morning, cells were introduced to hygromycin at a 
concentration of 10 μL/mL in media to ensure successful transduction. The PC-9-Br line 
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was transduced with firefly luciferase plasmid from addgene (32904) by the methods in 
Chapter 5.2 and selected for successful incorporation with G418 at 10 μL/mL. The 
MDA-MB-231 cell line was pre-transduced with Fluc and kindly provided by Dr. Patricia 
Steeg from the NIH. Cells were visualized in the IVIS Spectrum CT for luciferase 
expression prior to injection into mice. Firefly D-luciferase potassium salt was purchased 
from Perkin Elmer (Waltham, MA). All chemicals and reagents were of analytical grade 
and used as supplied. 
Cell Culture 
 The JIMT-1-Br and MDA-MB-231-Br brain-seeking breast cancer lines were a 
kind gift from Dr. Patricia Steeg at the National Cancer Institute. The U251 glioblastoma 
line was provided by Dr. Gordon Meares at West Virginia University. The PC-9-Br lung 
cancer line was provided by Dr. Lori Hazlehurst at West Virginia University. JIMT-1-Br, 
MDA-MB-231-Br, and U251 cells were grown in DMEM with 10% fetal bovine serum 
and 5% penicillin-streptomycin, along with hygromycin at 10 μL/mL. PC-9-Br cells were 
grown in RPMI with 10% FBS, 5% penicillin-streptomycin, and G4918 at 10 μL/mL. All 
cells were used in passages 1-15, utilized at 70-80% confluence, and maintained at 37oC 
with 5% CO2.  
Brain Tumor Models 
 Female athymic nu/nu mice were purchased from Charles River Laboratories 
(Wilmington, MA). All animals were approximately 6-8 weeks on time of model 
initiation. Mice were anesthetized under 2% isoflurane and injected with 150,000-
175,000 cancer cells via the cardiac left ventricle using a stereotactic device (Stoelting, 
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Wood Dale, IL). The same stereotactic device was used to inject 500,000 cells in the 
intracranial model. U251 cells were injected slowly through the cranium approximately 
1.5 mm below and 1mm to the right of bregma at 1 μL/minute for a 5-minute time period. 
Animals were monitored until fully recovered. Experiments were conducted under the 
institutional Animal Care and Use Committee protocol (WVU #1604001892). All 
procedures performed in studies involving animals were in accordance with the ethical 
standards of the institution or practice at which the studies were conducted. This article 
does not contain any studies with human participants performed by any of the authors. 
In-vivo pharmacokinetics 
 Bioluminescence was captured and quantified on the IVIS Spectra CT 
(PerkinElmer). Animals were anesthetized and laid supine on the imaging field, then 
given IP injections with 150 mg/kg of D-luciferin. Immediately after injection, image 
acquisition was initiated and photon emission was captured every 1-5 minutes for a 45-
60-minute sequence. Signal was captured using auto exposure, medium binning, F/Stop 
1, on Stage D. A region of interest was drawn around the cranium at each time point and 
photon emission was collected. This region of interest is defined as radiance 
(photons/sec/cm2/steridian) [19]. After radiance collection each animal’s signal was 
additionally normalized from peak bioluminescence signal for between-groups 
comparison and plotted over time of capture (Fig. 3.1). Area Under the Curve (AUC) was 





  To correlate in-vivo bioluminescence with in-vitro assays, pharmacokinetic 
profiling of these cell lines were performed on clear-bottom black 96-well plates (B-D 
#353220). Cancer cells were seeded at a concentration of 5,000 cells per well and 
incubated overnight. The following day, D-luciferin at 15 µg/100 µL was given to each 
well and immediately imaged on the IVIS Spectrum CT every 1 minute for a 30-minute 
sequence, using auto exposure, medium binning, F/Step 1, and on Stage D. Signal at each 
minute was averaged across 96 wells, then plotted over time as radiance 
(photons/sec/cm2/steridian) and then separately normalized for additional comparison.  
Exponential decay 
The exponential decay equation Xt*e
-kt, was modified for bioluminescence: Pt*e
-
kt; where Pt and k represents the amount of photons/second at time t. In vivo, k represents 
absorption (α) or elimination (ß); in-vitro this represents fast (Kfast) or slow (Kslow) 
elimination. This equation was applied to radiance and normalized values to obtain an α 
absorption slope value for each model. 
Statistics 
 The D’Agostino and Pearson omnibus normality test was conducted to confirm 
Gaussian distribution of values prior to calculations. A one-way ANOVA for multiple 
comparisons using Tukey’s or Dunnet’s multiple comparisons test was performed to 
compare radiance and normalized kinetic curves and peaks. Time within bioluminescence 
values statistically insignificant from peak values indicates a duration of minimal error. 
Error range was calculated by averaging the range of signal in 10-minute intervals. A 
one-way ANOVA was performed to compare each model’s in-vivo and in-vitro AUC 
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values. To calculate α and ß slopes for in-vivo luciferin kinetics, one-phase kinetic 
modeling was used. A two-phase kinetic modeling was used for in-vitro kinetics to define 
Kfast and Kslow. Significance for all tests was defined as a p < 0.05. GraphPad Prism 6.0 
was used to calculate all statistics and produce all graphs.  
3.3 Results 
 Peak bioluminescence occurs faster in the intracranial model compared to 
metastatic models  
To determine peak BLI timing, we injected Fluc-transduced tumor-bearing mice 
with D-luciferin and captured the rate of photons emitted through time (radiance). For 
distinguishing purposes, data was normalized and all points are plotted at 4-6 minute 
intervals. Minimal-error imaging is defined as signal not statistically significant (p < 
0.05) from peak value. Radiance data is shown in Fig 3.2. Significant variation exists 
between and within animal groups, so results will focus on normalized data. In the MDA-
MB-231-Br line (n = 4), peak BLI occurred at 20 ± 2.7 minutes, with significant signal 
difference occurring before 15 minutes and after 25 minutes (Fig. 3.3a). In the JIMT-1-
Br line (n = 3), peak BLI occurred at 16 ± 1.2 minutes, with a minimal-error duration of 
10 to 24 minutes (Fig. 3.3b). In the PC-9-Br line (n = 4), peak BLI occurred at 12 ± 3.1 
minutes, with minimal-error occurring before 5 minutes and after 24 minutes. (Fig. 3.3c). 
For the U251 line (n = 3), peak BLI occurred at 9 minutes, with significant signal 
difference occurring before 5 minutes and after 21 minutes (Fig. 3.3d). The results are 
summarized in Table 3.1. The amount of signal captured (Pmax) at peak BLI follow peak 
BLI timing (Table 3.2). Normalized in-vivo data is represented in Table 3.3. 
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Optimal bioluminescence capture timing is longer in the metastatic model 
compared to the intracranial model  
After creating luciferin pharmacokinetic curves for each model, normalized signal 
ranges from peak was calculated in 10-minute blocks. It was found that the 10-20 minute 
time block contained the smallest range of signal in most models, displaying an intensity 
above approximately 95% of peak BLI (Table 3.4). Similar variability of signal and 
optimal timing were described in another study of luciferin BLI [20]. Time correlating to 
> 95% of peak BLI signal was 15-25 minutes for the MDA-MB-231 model (Fig. 3.3a), 
12-20 minutes for the JIMT-1 model (Fig. 3.3b), 9-14 minutes for the PC-9 model (Fig. 
3.3c), and 7-12 minutes for the U251 model (Fig. 3.3d); summarized in Table 3.1. 
 In-vitro bioluminescence reaches a plateau at similar times to in-vivo peak 
values 
 To correlate in-vivo models with their in-vitro counterparts, 5,000 cancer cells 
were added to 96 clear-bottom black-welled plates and incubated overnight. The 
following day, luciferin was added, followed by quantification and data normalization. 
Qualitative 5-minute time lapses are shown (Fig. 3.4a). A plateau was defined as signal 
change less than 1% between normalized values. In the PC-9 model, BLI signal rapidly 
dropped off until reaching plateau at 70% of initial peak value at 14 minutes (Fig. 3.4c). 
This timing qualitatively corresponds exactly with the in-vivo peak seen in this model. In 
the U251 model, BLI signal rapidly dropped off until reaching plateau at 43% of initial 
peak value at 7 minutes (Fig. 3.4d). This timing qualitatively agrees with the in-vivo peak 
luminescence in this model seen at 9 minutes. This qualitatively parallels the in-vivo peak 
seen at 20 minutes in this model. The JIMT-1 line diverges from these findings. While 
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the in-vivo peak occurs at 16 minutes, the in-vitro plateau begins at 7 minutes and lasts 
until 18 minutes, at which point signal begins to fall. Signal within the plateau was 85% 
of initial peak value (Fig. 3.4b). 
 Normalized in-vivo a slopes and radiance ß slopes are correlated with peak in-
vivo bioluminescence times 
 With regards to absorption slopes, PC-9 had the fastest slope (0.3689) and JIMT-1 
had the slowest slope (0.0919), with U251 (0.1476) and MDA-MB-231 (0.2161) in 
between (Table 3.2). A linear regression revealed an r2 of 0.01, indicating no correlation. 
Normalized α values resemble radiance α values: the PC-9 line had the steepest α slope of 
0.4862, while the JIMT-1 line had the lowest α slope of 0.11. The α of the MDA-MB-231 
line of 0.2017 and U251 of 0.2980 fell in between (Table 3.3). A linear regression of 
peak luminescence times and normalized α slope values produced an r2 of 0.32, 
indicating modest correlation. Radiance data shows that the U251 model has the highest ß 
value of 0.022 photons/sec, whereas the MDA-MB-231 model has the lowest ß value of 
0.0127 photons/sec (Table 3.2). The radiance ß of the PC-9 (0.0128) and JIMT-1 
(0.0220) fell in between (Table 3.2). A linear regression of radiance ß and peak 
luminescence times had an r2 of 0.33, indicating modest correlation. In contrast, the 
normalized ß luciferin elimination slope was the slowest in the PC-9 line at 0.0036 
followed closely by the MDA-MB-231 of 0.0053, then U251 at 0.0137, and was the 
fastest in the JIMT-1 at 0.0192 (Table 3.3). A linear regression of normalized ß slope 
values and peak bioluminescence times produced an r2 of 0.02, indicating no correlation.  




Radiance was plotted over time and the AUC (total photons given off during 
imaging time) for length of capture was quantified. The AUC0-60 was the highest in the 
U251 (1.2 x108) and lowest in the MDA-MB-231 model (4.4 x 103), with JIMT (7.4 x 
107) and PC-9 (3.0 x 106) falling in between (Table 3.2). This agrees with peak in-vivo 
bioluminescence timing, and a linear regression analyses produced an r2 of 0.37. A one-
way ANOVA showed significant differences in radiance AUC between all models (p < 
0.05). In contrast, the normalized AUC0-60 was the highest in the MDA-MB-231 (3750) 
and PC-9 (3550) cell lines, followed closely by JIMT-1 (3120), and lowest in the U251 
line (2760) (Table 3.3). A linear regression of peak bioluminescence times and 
normalized AUC0-60 resulted in an r
2 of 0.52. A one-way ANOVA showed significant 
differences between these curves, with the MDA-MB-231 AUC significantly different 
from the JIMT-1 and U251 AUCs, the JIMT-1 AUC showing significant difference to 
MDA-MB-231 and PC-9 AUCs, and the U251 AUC showing statistically significant 
difference from the MDA-MB-231 and PC-9 AUCs (p < 0.05) (Fig. 3.5). 
 In-vitro two-phase decay Kfast values correlate with peak in-vivo signal times 
 After plotting radiance and normalized values against time for each in-vitro 
experiment, two-phase decay kinetics were utilized to measure decay until plateau (Kfast) 
and decay from plateau (Kslow), to elucidate if decay constants correlated with peak in-
vivo luminescence time. The largest radiance Kfast was seen in the U251 model (0.4717), 
the smallest in the PC-9 model (0.1810), with MDA-MB-231 (0.3142) and JIMT-1 
(0.3830) falling in between (Table 3.2). A linear regression produced an r2 of -0.53, 
indicating larger Kfast values are correlated with faster peak bioluminescence timing. The 
largest normalized Kfast was seen in the U251 model (0.4717) and the slowest in the 
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MDA-MB-231-Br model (0.1352), which was followed by JIMT-1-Br (0.1652) and PC-9 
(0.1790) (Table 3.3). The values of normalized Kfast were plotted against peak in-vivo 
bioluminescence times resulting in a linear regression producing an r2 of 0.66.  
3.4 Discussion 
D-luciferin is a non-toxic marker utilized for both in-vitro and in-vitro 
bioluminescence measurements. By capturing photon emission and visualizing emission 
trends through time, longitudinal assessment of therapy efficacy can be performed. Two 
issues with in-vivo and in-vitro BLI collection are addressed in this study: the optimal 
time to initiate signal collection, and the duration in which signal will not vary 
significantly from peak photon emission time. Both of these issues are dependent on 
which type of luciferase is used for BLI data.  
Different types of luciferase exist. The three most commonly used are Rluc, 
Gaussia Gluc, Fluc, the latter is also termed luc2 [21, 22]. Rluc and Gluc metabolize 
coelenterazine to give off an intense burst of light before rapidly returning to near-
baseline levels, termed “flash kinetics” [23]. This makes Rluc and Gluc difficult to work 
with, as small differences in imaging time can cause significant quantification 
differences. In contrast, Fluc metabolizes D-luciferin to produce light and slowly 
decreases in signal intensity, termed “glow kinetics” [23]. Though Fluc does not produce 
as intense an initial signal as Rluc or Gluc, it is the most common vector for luciferin BLI 
due to the maintenance of signal intensity. 
Photons produced by Fluc are away from the blue absorption values of Rluc 
(λmax = 480 nm) and Gluc (λmax = 460 nm) [22, 24, 25]. This wavelength range 
overlaps with fluorescence with structural proteins such as collagen and elastin, as well as 
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enzymes such as NADH and NADPH, and other proteins such as lipofuschin [26, 27]. 
Tissue often displays “auto-fluorescence”, which can generate significantly obstructive 
background signal [28]. The production of photons during in-vivo fluorescence brain 
imaging is often attenuated by the cranium [29]. In order to quantitatively image the 
brain, thinning of the cranium and a window placement is often required, though data 
gathered may not be specific unless used in near-infrared ranges [30]. This is not optimal 
for brain metastatic models especially during longitudinal studies due to the number of 
tumors produced and the invasiveness of the procedure. The spectra range of photon 
emission further supports the use of Fluc over Rluc or Gluc as longer wavelengths (> 600 
nm), especially those in the red and far-red spectrum, are better able to transmit through 
tissue compared to blue and green spectra [31]. Efforts are made to create Fluc analogs 
that produce spectra even closer to the 700 nm range, reaching edges of infra-red 
wavelengths [32, 33]. 
Of interest, we were able to fit, and apply, our data to a linear exponential decay 
curve. The exponential equation Xt*e
-kt is utilized in many disciplines, including 
radioactivity, pharmacological half-life, and fluorescence [34]. In this equation, Xt is a 
quantity at time t, and k is a value indicating growth or decay [34]. Adapted for 
bioluminescence, the equation becomes Pt*e
-kt, where Pt and k represents the amount of 
photons/second at time t. In vivo, k can represent absorption (α) or elimination (ß); in-
vitro this can represent fast (Kfast) or slow (Kslow) elimination. Visualized, k is represented 
by the slope connecting data points. Thus, the steeper the slope, the faster the rate 
constant.   
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The timing of signal capture onset is essential, as seen by the large, rapid increase 
of photon production occurring within the first 10 minutes after luciferin injection in all 
models. This timing is crucial whether working with the “flash” Gluc and Rluc luciferin 
reporters due to their rapid onset-offset characteristics. Signal discrepancy from peak BLI 
is the lowest during the 10- to 20-minute time block, following an ebb-and-flow pattern 
as signal returns to baseline; this time block thus represents the optimal time for BLI 
acquisition as maximum signal will be captured. The time to reach peak BLI is generally 
delayed in the metastatic models compared to the intracranial model, but have nearly 
double optimal imaging collection periods.  
It is possible that BLI kinetics of the intracranial model is due the larger number 
of cells injected and/or the type of tumor lesion formed. While the 150,000-175,000 cells 
administered in the intracardiac metastatic model produce more numerous, small lesions 
[35], the 500,000 cell intracranial model creates one large tumor [36]. The size of tumor 
may also account for the narrow optimal imaging time and the large minimal-error 
window, as a larger tumor may utilize more luciferin in a given period of time, as 
evidenced by the U251 radiance Pmax and AUC. This is the impetus for data 
normalization, as each animal between and within models is placed on the same scale for 
easier and more accurate comparison [37].  
Entry to the brain tissue is restricted due to the presence of the blood-brain barrier 
(BBB). The BBB is composed of endothelial cells attached by tight junctions, astrocytic 
foot processes, and enzymes to efflux and degrade molecules [38]. As cancer cells grow, 
they often create new vasculature in a process called angiogenesis. These immature 
vessels are compromised, and the blood-tumor barrier (BTB) allows some permeation of 
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restricted molecules into tumor and brain tissue [38]. Permeability of a substance through 
the BBB or BTB can be estimated using Lipinski’s Rule of 5s, or visualized and 
quantified using radioisotope data. 
Lipinski’s Rule of 5 are used to estimate if molecules are able to permeate the 
blood-brain barrier (BBB). An optimal molecule should have a molecular weight lower 
than 500 daltons, lipophilicity measured by logP > 5, not donate more than 5 hydrogen 
bonds, and not accept more than 10 hydrogen bonds. [39] It should be noted that most 
BBB-permeant molecules have a logP of approximately 2.5 [40]. D-luciferin has a 
molecular weight of 280 Da, donates 2 hydrogen bonds, accepts 5 hydrogen bonds, and 
has a logP of 0.5, fulfilling three of these four rules [41]. A variant of logP, logD is 
calculated using a buffered solution and represents a molecule’s lipophilicity at pH 7.4. 
As this mimics physiological conditions, logD may be more useful than logP in 
determining the BBB-penetrating capability of a molecule. A logD of 1-4 indicates likely 
BBB permeability [42]. D-luciferin has a logD of approximately -2.34 at physiologic pH, 
indicating high water solubility, which corresponds with the report of radioisotope 14C-D-
luciferin accumulating at comparatively low amounts into brains of naïve nude mice, the 
same type used in these experiments [43].  
The association between vasculature and BLI is well documented. Anti-
angiogenic agents cause both a significant delay in peak timing as well as reduced levels 
of photon emission [20]. This is confirmed by visualizing reduced blood flow by 
magnetic resonance imaging [20]. Additionally, this study found up to 60% variability 
between consecutive imaging points, with a 95% confidence interval near peak showing 
≤ 20% variability, which are similar to our findings [20]. A VEGFR-luc transgenic stroke 
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model showed that increased new vessel formation was associated with increased photon 
emission, confirmed with MRI imaging showing enhanced T2 values [44]. An 
intracranial glioblastoma model found that luciferin BLI intensity increased as tumor 
angiogenesis occurred [45], and luciferin has been used for ex vivo imaging in avascular 
tissue such as intervertebral disks [46].  
Heterogeneity of tumor vasculature may be responsible for the differences in 
delivery of D-luciferin and the kinetic curves. The U251 tumor vasculature is more 
permeable to the small 14C-aminoisobutyric acid molecule compared to metastatic 
models). Using luciferin for in-vitro experiments removes dependencies of absorption 
and vasculature on in-vivo BLI. Maximum photon emission begins directly after addition 
of D-luciferin. This is seen in the PC-9 and U251 models which then stabilized to a 
plateau, the timing of which is similar to their in-vivo peak time. Rather than beginning 
signal capture immediately after D-luciferin administration, for minimized error and 
optimal collection, in-vitro models should be imaged upon reaching a signal plateau, 
which generally resembles in-vivo peak time.  
Both radiance and normalized AUC0-60 is correlated to peak bioluminescence 
timing. The U251 model had the smallest AUC0-60 but the fastest peak time, while the 
MDA-MB-231-Br model had the highest AUC0-60 and most delayed peak time. This 
suggests that despite same Fluc incorporation, cells metabolize luciferin at different rates, 
supported by significant differences in in-vivo peak times (highest in MDA-MB-231, 
lowest in U251) and in-vitro Kfast values (lowest in MDA-MB-231, highest in U251).  
In conclusion, we characterized luciferin bioluminescence curves in brain tumor 
models and their in-vitro counterparts, highlighting intra-model similarities and inter-
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model differences. Future studies will focus on determining vascularity differences of 
preclinical brain metastases and primary glioblastoma, Fluc copy numbers of each cell 




 We report the luciferin pharmacokinetics for emerging brain metastases models 
and an established intracranial brain tumor model, but there are three key differences. 
Peak bioluminescence occurs later, optimal imaging time is longer, and time of 
minimized error is shorter in the metastatic model. In-vitro imaging times exhibit first-
order kinetics in which signal plateau corresponds with in-vivo peak timing, revealing 
consistent models. The time to in-vitro plateau and in-vivo peak signal production is 
unique to each cell line and cannot be substituted without incurring significant error. 
These parameters are critical to consider as the preclinical models are used in 
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Figure 3.1. Representative time-course of bioluminescence capture and 
quantification.  
150 mg/kg of d-luciferin was administered via intraperitoneal injection into a mouse 
bearing the MDA-MB-231 brain-seeking tumor line. A region of interest was drawn 
around the skull to quantify photon emission. Counts are displayed as low (blue) to high 
(red). Data was normalized to peak values of each animal and plotted against time. The 
peak value can be seen at 20 minutes (Panel 4), with optimal imaging time occurring 
between 15 (Panel 3) and 25 minutes (Panel 6). 
  

































Figure 3.2. Radiance luciferin pharmacokinetics for brain tumor models.  
Photons emitted per second were plotted over time in the (A) MDA-MB-231-Br, (B) 
JIMT-1-Br, (C) PC-9-Br, and (D) U251 models. Large variability exists between animals 
in the same group. Peak signal production is distinguished as a star-shape in each graph. 




Figure 3.3. Normalized luciferin bioluminescence profiles for brain tumor models.  
(A) The metastatic breast lines MDA-MB-231 and (B) JIMT-1 have delayed peak times 
but longer optimal imaging windows, while the (C) PC-9-Br and (D) U251 models 
feature the fastest onset to peak times and smallest optimal imaging window time. Green 
represents optimal signal capturing time (above 95% of peak) while yellow represents 
values that are insignificant (p < 0.05) from peak intensity but fall outside of the optimal 
range. Peak BLI is distinguished as a star-shape in each graph. Data was analyzed using 
one-way ANOVA with Dunnet’s multiple comparison test. All data points represent 





Figure 3.4. In vitro luciferin kinetics corresponds with in vivo bioluminescence.  
Qualitative 5-minute imaging for imaging duration is shown for models (A). The JIMT-1 
(B), PC-9 (C), and U251 (D) models display first-order kinetics with a rapid followed by 
a slow elimination phase. Plateau was defined as a ± 1% change from previous signal. In 
vitro models reach signal plateau at similar times to their in vivo peak times (inset 
arrows). All data points represent mean ± SD (n = 96), with error ≤ 1% residing within 




Figure 3.5. Radiance and normalized AUC comparisons.  
In vivo radiance (A) and normalized (B) bioluminescence AUCs were calculated, as were 
in vitro radiance (C) and normalized (D) bioluminescence AUCs for comparison. In both 
models, U251 shows the highest radiance AUC and lowest normalized AUC. A one-way 
ANOVA using Dunn’s multiple comparisons showed AUC within a plot are significantly 
different from each other (p < 0.05) except for normalized in vivo AUCs. Error ≤ 1% 








Table 3.1. Timing of luciferin imaging for in vivo cancer cell models.  
Bioluminescence imaging for each cell line were characterized for time to peak signal value, signal statistically insignificant (p 
> 0.05) from peak value defined as minimal error time, and time above 95% of peak value defined as optimal imaging time. 
Metastatic models feature delayed peak timing compared to the intracranial model. Lengthier BLI peak times are associated 
with shorter minimal error time but longer optimal imaging time. An ANOVA with Dunn’s multiple comparison test was 




















4 Intracardiac 20 15 – 25 15 – 25 
JIMT-1-
Br 
3 Intracardiac 16 10 – 24 12 – 20 
PC-9-Br 4 Intracardiac 12 5 – 24 9 – 14 
























0.2161 1.16 ± 
0.32 
x102 





0.0919 2.25 ± 
1.34 
x106 





0.3689 8.52 ± 
1.29 
x105 
0.0128 2.99 ± 1.03 
x106 
0.1810 0.1790 
U251 0.1476 4.61 ± 
5.31 
x106 
0.0220 1.19 ± 0.34 
x108 
0.4717 0.4717 
Table 3.2. Radiance pharmacokinetic data for tumor models.  
BLI signal was plotted as radiance (photons/sec/cm2/steridian) against time. One-phase 
kinetic modeling was used to plot in vivo signal rate to peak (α) and elimination rate (ß), 
and two-phase kinetic modeling for as in vitro fast (Kfast) and slow (Kslow) signal 
deterioration. Area under the curve (AUC) represents total photon emission during signal 
capture. The peak radiance (Pmax), AUC, and in vitro kinetics were highest in the 
intracranial U251 model while ß was lowest. A one-way ANOVA using Dunn’s multiple 
comparison showed the AUC of each model was statistically different from one another 
(p < 0.05). All data is based on n of 3-4 per model.
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Cell Line Normalized 
Absorption 





AUC ± SEM 
Normalized curve 







0.2017 0.0053 3749 ± 118 JIMT-1, U251 0.1279 0.1279 
JIMT-1-Br 0.1054 0.0192 3120 ± 40 MDA-MB-231, PC-9 0.1971 0.0119 
PC-9-Br 0.4862 0.0036 3545 ± 83 JIMT-1, U251 0.1817 1.46 x10-16 
U251 0.2980 0.0137 2757 ± 89 MDA-MB-231, PC-9 0.4713 1.17x10-16 
Table 3.3. Normalized pharmacokinetic data for tumor models.  
Signal captured during BLI was normalized to percent based on peak and plotted against time to create a normalized 
pharmacokinetic profile for each tumor model. In contrast to radiance data, the intracranial U251 model has the largest α and 
AUC, while the MDA-MB-231 model has the largest AUC. A one-way ANOVA using Dunn’s multiple comparison showed 




Cell Line 0-10 10-20 20-30 30-40 40-50 50-60 
MDA-MB-
231-Br 
53.2% 26.5% 16.5% 19.5% 17.6% 14.6% 
JIMT-1-Br 75.2% 4.3% 23.8% 27.7% 17.5% 8.1% 
PC-9-Br 73.7% 9% 15.3% 15.5% 14.5% 10.6% 
U251 78.9% 17.5% 21.0% 15.9% 9.2%  
Table 3.4. Signal range during bioluminescence imaging.  
After signal acquisition, data was normalized and plotted. Percent range of 10 minute 
blocks was calculated. The highest range occurs in the first 10 minutes in all models, 
followed by the 10-20-minute block which has the lowest range in most models. Potential 
error is greatest if imaging in the first 10 minutes, but minimal in the 10-20-minute block, 




EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THREE 
PRECLINICAL BREAST CANCER BRAIN METASTASES MODELS 
4.1 Introduction 
 Breast cancer is both the second-most diagnosed cancer and second-most cause of 
cancer death in women resulting in an estimated 250,000 new cases and 40,000 deaths in 
2017. [1] Brain metastases occurs in approximately 10-20% of all breast cancer cases. [2] 
Prognosis is typically poor and often dependent on metastatic lesion number, size and cell 
phenotype. [3] Triple negative breast cancer (TNBC) and human epidermal growth factor 
receptor (HER2)-positive metastases occur more frequently, numerously, and are 
associated with the shortest survival. [3-5] Treatment of breast cancer brain metastasis 
(BCBM) includes surgical resection, whole brain radiation therapy (WBRT), stereotatic 
radiation, and systemic and targeted chemotherapy. [6, 7] TNBC makes up approximately 
10-15% of breast cancer cases and 20% of BCBM [8] while HER2+ makes up 
approximately 20% of breast cancer cases and up to half of patients develop brain 
metastases. [9, 10] Despite advances in treatment, survival after diagnosis of BCBM 
ranges between 4 and 26 months. [3-5] The resistance of BCBM to chemotherapy is 
mainly due to the physiochemical activities of the blood-brain barrier (BBB) and blood-
tumor barrier (BTB). [4, 5] 
The physical BBB is composed of endothelial cells joined by tight junctions, a 
basement membrane, pericytes, and astrocytic foot processes. [11] Efflux transporters 
such as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), and intracellular 
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enzymes (phosphatases, oxidases) comprise the chemical portion of the BBB, further 
restricting brain penetration of chemotherapy. [11, 12] In brain metastases, vasculature is 
often compromised, resulting in the BTB. Though often described as “leaky”, vascular 
disruption in the BTB does not always significantly impact chemotherapeutic penetrance 
due to intact efflux activity. [13, 14] Pharmaceutical development of chemotherapy that 
offers enhanced brain penetration often consists of active agents conjugated to polymers 
like polyethylene glycol (PEG). [15] 
Etirinotecan pegol consists of four arms in which each arm is composed of a PEG 
polymer, a cleavable ester linker, and a molecule of irinotecan. As a 20 kDa molecule, 
penetration of etirinotecan pegol into normal tissue is limited by intact vasculature but 
has less difficulty penetrating tumor vasculature. [16, 17]  Upon administration, ester 
cleavage slowly releases irinotecan which is further metabolized to the active SN-38 
molecule, providing sustained topoisomerase I inhibitory activity. [18] Etirinotecan pegol 
has shown efficacy as monotherapy in chemotherapy-resistant metastatic ovarian [19] 
and breast cancer [20]. The BEACON trial did not show significant survival difference of 
etirinotecan pegol against physician’s choice (eribulin, vinorelbine, gemcitabine, 
paclitaxel or docetaxel) in the treatment of advanced breast cancer [16] but post-hoc 
analysis of data showed that BCBM patients could benefit from therapy. [21]  
As previously reported, etirinotecan pegol dosed at 50 mg/kg equivalents of 
irinotecan in a preclinical triple negative BCBM model provides SN-38 concentrations 
similar to the 145 mg/m2 dose used in the BEACON trial, which lead to improved 
survival against placebo and conventional irinotecan 50 mg/kg. [17] Adapting the intent 
of the BEACON trial, we hypothesized that this dose of etirinotecan pegol would 
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significantly improve survival when compared to eribulin, vinorelbine, gemcitabine, or 
docetaxel monotherapy in the human triple negative MD-MBA-231-BrLuc, murine triple 
negative 4T1-BrLuc, and human HER2+ JIMT1-BrLuc BCBM models.  
Herein, we present evidence that etirinotecan pegol 50 mg/kg preferentially 
accumulates into metastatic lesions compared to non-tumor brain parenchyma. 
Etirinotecan pegol increases median survival in both MDA-MB-231-BrLuc and JIMT-1-
BrLuc human breast-brain metastases models (p < 0.05) compared to traditional 
physician’s choice chemotherapy (p > 0.05), but does not improve survival in the murine 
4T1 model (p > 0.05). 
4.2 Methods and Materials 
Animals 
Female athymic nude mice aged 4-8 weeks weighing 20-25 grams were bought 
from Charles River Laboratory (Kingston, NY) and housed for a minimum of 72 hours to 
facilitate acclimation prior to intracardiac injection. Mice were housed in microisolator 
cages with a 12-hour light/dark cycle and received sterilized food and water ad libitum in 
accordance with West Virginia University’s Animal Care and Use Committee (ACUC 
protocol 13–1207). Upon reaching survival endpoints animals were euthanized by 
ketamine (100 mg/kg) and xylazine (8 mg/kg) mixture. All animal experiments were 





Firefly luciferase transfected into the human metastatic brain-seeking MDA-MB-
231-BrLuc cell line, and was kindly provided by Dr. Patricia Steeg from the National 
Institutes of Health (NIH). Similar transfection was done to JIMT1 cells to create the 
JIMT1-BrLuc line, and the 4T1 line to create the 4T1-BrLuc line. Cells were kept at 37o 
in 5% CO2, grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum and 5% penicillin-streptomycin. All cells used for in vivo and in 
vitro experiments were between passages 5 to 10. 
In-vitro toxicology 
 5,000 cancer cells per well were seeded into a 96-well plate. Chemotherapy was 
dissolved in negligible amounts of DMSO and prepared in media. For consistency, the 
same amount of DMSO was added to control media.  After addition of chemotherapy, 
plates were incubated for 72 hours. On endpoint, 50 μg/50 μL of MTT was added to each 
well and allowed to incubate for a further 2 hours. Wells were then aspirated and 100 uL 
of DMSO was added to each well for to solubilize the purple formazan crystals. After 
gentle shaking for an hour, wells were analyzed for absorbance at 570 nm. Concentration 
curves were plotted and IC50 values were calculated using a four-phase non-linear 
analysis.  
Stereotactic intracardiac injection 
Mice were induced and maintained by inhaling 2% isoflurane anesthesia and 
placed in a stereotactic apparatus (Stoelting). 1.75x105 MDA-MB-231-BrLuc, JIMT1-
BrLuc, or 4T1 cells in 100 uL of PBS were measured by an Invitrogen Countess I 
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(ThermoFischer) and then injected into the left ventricle by approximation or ultrasound 
guidance. [17] 
Drugs and dosing 
Gemcitabine, docetaxel, and vinorelbine were acquired from SelleckChem. 
Eribulin was acquired from Adooq BioSciences. Lapatinib was acquired from ApexBio. 
Etirinotecan pegol was provided by Nektar Therapeutics. Saline was chosen as the 
vehicle. Gemcitabine, vinorelbine and etirinotecan pegol were dissolved in saline. 
Docetaxel was dissolved in 5% ethanol/5% Tween 80/90% saline. Eribulin was dissolved 
in 5% ethanol/15% distilled water/80% saline. Vinorelbine 10 mg/kg [22, 23], docetaxel 
10 mg/kg [24-26], and etirinotecan pegol 50 mg/kg equivalent of irinotecan were dosed 
every 7 days via tail vein; eribulin 1.5 mg/kg [27] and Gemcitabine 60 mg/kg [28] were 
injected every 4 days via intraperitoneal injection. Lapatinib was suspended in 0.1% 
Tween 80 and 1% hydroxypropylmethylcellulose in water, dosed orally twice daily at 
100 mg/kg. [29] Dosing was initiated on Day 21 (Week 3) for the MDA-MB-231-BrLuc 
group, on Day 14 (Week 2) for the JIMT1-BrLuc group, and on Day 3 for the 4T1-BrLuc 
group (Table 4.1). All doses were made fresh on the day of administration and 
administered approximately half an hour after luciferin imaging. 
Imaging and Survival 
Animals were given a 150 mg/kg injection of D-luciferin potassium salt 
(PerkinElmer, Waltham, MA) via intraperitoneal injection and placed into 2% isoflurane 
for sedation. After 10-15 minutes to ensure luciferin circulation, animals were then 
transferred to the IVIS Lumina II (PerkinElmer) and bioluminescence imaging (BLI) was 
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performed. BLI was taken twice weekly to measure tumor burden. Regions of interest 
(ROI) were drawn based on cranial circumference and BLI is reported as radiance 
(photons/sec/cm2/steradian).  
Autoradiography 
 Animals were anesthetized and given 10 μCi of 14C-etirinotecan pegol via femoral 
vein injection. Mice were allowed to recover while the radioactive drug circulated for 24 
hours. At the endpoint, mice were again anesthetized and the descending aorta was 
clamped. Phosphate buffer saline was infused via left ventricle at 5 mL/min for 2 minutes 
to provide a washout. Brains were then extracted and frozen to be sliced in 20 μm slices, 
then placed in autoradiography cassettes to develop for 21 days. Cresyl violet stains were 
used to trace tumor areas, which were then overlaid on autoradiographic slides for use by 
MCID software for analysis.  
Statistics 
Survival analysis was plotted on a Kaplan-Meier curve and statistically compared using 
log-rank statistics. All results and statistical analysis were performed on GraphPad Prism 
6.0, and were considered statistically significant at p < 0.05. 
4.3 Results 
In-vitro sensitivity to SN-38 correlates with in-vivo survival efficacy 
To determine sensitivity of cell lines to BEACON chemotherapy, MTT 
toxicology was performed as outlined in the methods and materials. The MDA-MB-231-
BrLuc line was the most sensitive to NKTR-102’s parent drug irinotecan (1 μM ± 0.11 
μM) and active metabolite SN-38 (10.5 nM ± 2.9 nM) compared to the 4T1-BrLuc (12.7 
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μM ± 0.47 μM and 24.9 nM ± 0.06 nM, respectively) and JIMT-1-BrLuc (39 μM ± 1.78 
μM and 222.8 nM ± 0.17 nM, respectively). The results are summarized in Table 4.2.  
Etirinotecan pegol prolongs survival of human triple negative and HER2+ breast 
cancer brain metastases, but not the murine triple negative model 
To evaluate our main aim in comparing the efficacy of our investigational drug to 
established chemotherapeutics, we injected MDA-MB-231-BrLuc, 4T1-Br, and JIMT1-
BrLuc cells as described. Tumor growth was monitored using bioluminescence (BLI) 
twice weekly starting on day 21 (Week 3) post-injection in the 231-Br line (Fig. 4.1A), 
14 days (Week 2) in the JIMT1-Br line (Fig. 4.3A), and 3 days in the 4T1-Br line (Fig. 
4.5A). In 231-Br vehicle animals, tumor burden increased nearly 1000-fold from baseline 
(Fig. 4.1B) resulting in a median survival of 40 days (Fig. 4.2). Similarly, animals treated 
with gemcitabine in this cell line had bioluminescence increase nearly 1000-fold (Fig. 
4.1B), but survived longer (median survival 68 days, Fig. 4.2). Eribulin, docetaxel and 
vinorelbine treated animals had tumor burden increase nearly 100-fold with median 
survivals as 40.5, 39, and 43 days, respectively (Fig. 4.2). No animals in the 231-Br 
vehicle or conventional chemotherapy group survived beyond day 60. Etirinotecan pegol 
treated mice in the 231-Br model had bioluminescence plateau 10-fold above baseline 
(Fig. 4.1B) and median survival was 86 days (Fig. 4.2) with four mice (40%) surviving 
until the end of the trial.  In the JIMT1 model, dosing was initiated on day 14. Vehicle 
burden peaked a maximum of 10,000-fold from baseline (Fig. 4.2B) with a median 
survival of 28 days (Fig. 4.4). Bioluminescence in lapatinib mice peaked at 100-fold 
above baseline (Fig. 4.2B) with a median survival of 29 days (Fig. 4.3B). Etirinotecan 
pegol closely followed the bioluminescence curve of lapatinib in this model, but like in 
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the 231-Br group, prevented further increases in signal (Fig. 4.2B) with a median survival 
of 34 days (Fig. 4.4). In the 4T1-Br group, both NKTR-102 and conventional 
chemotherapy had similar bioluminescence curves aside from gemcitabine, which was 
significantly right-shifted but eventually reached similar maximum values (Fig. 4.5B). 
Survival corresponded with the bioluminescence curve for 4T1-Br, as gemcitabine’s 
median survival (28.5 days) was nearly double that of vehicle (15 days) and most other 
conventional chemotherapy agents (Fig. 4.6). The results are summarized in Table 4.3. 
Etirinotecan pegol accumulates preferentially in tumor tissue compared to brain 
parenchyma  
 To evaluate the distribution of etirinotecan pegol, 10 μCi of 14C-labeled drug was 
administered and circulated for 24 hours. After brain extraction, 20 μm slices placed in 
autoradiography cassettes and developed for 21 days. Cresyl violet staining was 
performed to outline tumor areas (Fig. 4.7A). Quantification of 20 tumors revealed that 
14C-etirinotecan pegol accumulated to 2603 ± 917 ng/g in tumor tissue and 220 ± 40 ng/g 
in control regions of brain (Fig. 4.7B), more than a 10-fold difference (Fig. 4.7C). 
4.4 Discussion 
The principal finding of the present experiment was that etirinotecan pegol 
significantly improved survival compared to vehicle and conventional chemotherapy 
groups in the human MDA-MB-231-BrLuc and JIMT-1-BrLuc groups, but not the 
murine 4T1-BrLuc group. In the MDA-MB-231-BrLuc group, etirinotecan pegol 
administration prolonged survival beyond double of any conventional chemotherapy 
group with nearly half of treated mice surviving until the end of the 90-day trial. 
Similarly, etirinotecan administration led to one mouse surviving in the JIMT-1 group 
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until the end of the trial. No conventional chemotherapy treatment mice of any cell line 
survived until the end of the trial. In both the MDA-MB-231-Br and JIMT-1-Br lines, 
etirinotecan pegol shows early control of tumor burden based on bioluminescence, which 
was sustained in the 231-Br model. The results of this study correspond with findings in 
our previous trial with etirinotecan pegol in the 231-Br model [17]. 
The timing of chemotherapeutic administration is crucial to its effects on survival. 
In order to prevent metastases, chemotherapy has to be given while cancer cells are still 
circulating or initially attaching to parenchyma, typically before two weeks in preclinical 
models [30]. In our model, metastases have been established and allowed to grow for up 
to three weeks prior to chemotherapy administration, mimicking clinical settings. Though 
lapatinib has shown efficacy in reducing lesion size and improving survival in HER2 
BCBM settings, the JIMT-1 cell line is intrinsically resistant to the drug and represents a 
pre-treated model, explaining why the drug did not improve survival compared to the 
vehicle in this setting [30, 31]. 
The 11-fold greater accumulation of 14C-etirinotecan pegol into tumor tissue 
compared to non-tumor parenchyma demonstrates that the drug is able to traverse the 
disrupted BTB to create its sustained effects. This replicates findings of the previous 
study using autoradiographic data in which 14C-etirinotecan pegol significantly and 
preferentially accumulated in brain metastases compared to non-tumor regions [17]. As 
expected, the sustained depot-like effects of pegylating irinotecan allowed for sustained 
SN-38 delivery to tumors, which led to superior tumor burden control as evidenced by a 
plateau in BLI in the 231-Br and JIMT-1 models. 
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Conventional irinotecan has typically not been used as part of a therapeutic 
regimen for BCBM, and has not demonstrated any significant improvements in 
increasing median survival in preclinical settings. [17, 32] However, liposomal irinotecan 
increased median survival by 13 days at equivalent doses to conventional irinotecan [32]. 
Additionally, liposomal irinotecan was found to increase and prolong the exposure of the 
active SN-38 metabolite compared to conventional irinotecan, which corresponds to the 
findings of the previous etirinotecan pegol study [17, 32]. This sustained exposure to SN-
38 is documented clinically in two Phase 1 [33] and two Phase 2 etirinotecan trials [19, 
20], and has led to liposomal irinotecan involvement in a clinical trial (NCT01770353).   
The discrepancy of NKTR-102 efficacy may be due to the origin of cell lines 
used. MDA-MB-231-BrLuc and JIMT-1 are human epithelial derived lines, whereas 
4T1-BrLuc is a murine derived line. Since NKTR-102 is a topoisomerase I inhibitor used 
in human cancer, it is possible that the administration of the drug did not have any 
significant effect in the murine model.  
Another possibility is NKTR-102 did not penetrate as readily into 4T1-Br tumors 
as it does in 231-Br tumors. While both cell lines create tumors in the brain, 4T1 tumors 
are more numerous and smaller, whereas 231 tumors are larger in size and fewer in 
number [34]. The smaller size and reduced vascularity of 4T1 tumors could restrict the 
large 20kDa NKTR-102 molecule from penetrating and effectively reducing tumor 
burden. This is not problematic for gemcitabine as it is a small molecule and readily 
uptaken by tumor cells due to its resemblance as a nucleotide, which may explain 
gemcitabine’s efficacy in the 4T1 model [35]. 
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Alternatively, the efficacy of etirinotecan pegol may be due to tumor 
aggressiveness. While the MDA-MB-231 and JIMT-1 lines take 14-21 days post-
intracardiac injection to establish brain metastases, the 4T1 line is quicker to form and 
grow tumors, with most treatment groups’ median survival occurring in this time period. 
It is possible that etirinotecan pegol works on slower-growing tumors, allowing for the 
release of SN-38 over time to appropriately achieve cytotoxic concentrations and effect. 
This phenomenon is known as enhanced permeation and retention (EPR).  
Compromised tumor vasculature allows for increased permeability and allow 
substances to create a reserve and slowly release for days to weeks [36, 37]. Clinically-
used dosage forms exhibiting EPR include encapsulation in liposomes (Myocet®), 
conjugation to polyethylene glycol (Onzeald®) or albumin (Abraxane®), or a 
combination of both, as is the case with pegylated liposomal doxorubicin (Doxil®) [36]. 
Preclinical and clinical evidence has shown that these formulations improve circulation 
half-life and extravasate in metastatic lesions, though effects on overall survival are 
ambiguous [36]. With autoradiographic evidence that etirinotecan pegol deposits and is 
retained in tumor tissue, along with sustained irinotecan and SN-38 levels in the tumor 
environment, we believe that the molecule achieves its tumoricidal effects through EPR. 
The continuous effects of etirinotecan pegol may also lead to a preventative phenomenon, 
as circulating cancer cells sensitive to the agent may be killed before extravasating and 
developing into metastases. 
Etirinotecan pegol is demonstrated to be efficacious in two preclinical models 
representing the most common types of BCBM. We have observed that etirinotecan 
pegol provides long systemic concentrations of irinotecan and SN-38. Our radiographic 
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data demonstrate etirinotecan pegol permeates through the compromised BTB and 
accumulates in BCBM, which we believe is responsible for the increase in survival 
compared to conventional chemotherapy and vehicle groups in the 231-Br and JIMT-1 
models. The translational findings of this trial are significant.  
 As targeted and novel chemotherapy agents surge in development, survival from 
brain metastases of breast cancer remains poor with a prognosis between 2 to 34 months. 
The post-hoc clinical findings from the BEACON trial, in combination with previous 
preclinical findings and this preclinical trial, support the use of etirinotecan pegol as a 
therapeutic option in the ongoing ATTAIN trial, which evaluates its efficacy against TPC 
to treat brain metastases from triple-negative and HER2+ breast cancer. 
4.5 Conclusion 
 Etirinotecan pegol accumulates in metastatic brain lesions and significantly 
improves survival compared to conventional chemotherapeutic agents in two human 
cellular models of triple-negative and HER2+ brain metastases of breast cancer. These 
data support the use of etirinotecan pegol in the Phase III ATTAIN trial.  
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Figure 4.1. Etirinotecan pegol reduces tumor burden in the MDA-MB-231-Br model 
compared to conventional chemotherapy and vehicle. 
(A) Following intracardiac injection of MDA-MB-231-Br cells and establishment of 
brain metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and 
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean 
BLI signal versus time in 231-Br mice treated with therapy. Treatment was initiated on 
day 21. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden in 
etirinotecan pegol-treated mice was significantly lower than conventional chemotherapy 





Figure 4.2. Kaplan-Meier survival curve of MDA-MB-231-Br mice treated with 
etirinotecan pegol and conventional chemotherapy.  
On day 21 after intracardiac injection of MDA-MB-231-Br cells, mice were treated with 
vehicle (saline, n = 8), docetaxel (10 mg/kg, n = 8), vinorelbine (10 mg/kg, n = 8), 
eribulin (1.5 mg/kg, n = 8), gemcitabine (60 mg/kg, n = 9), or etirinotecan pegol (50 
mg/kg, n = 10). Median survival time were 40 days for vehicle, 39 days for docetaxel, 43 
days for vinorelbine, 40.5 days for eribulin, 48 days for gemcitabine, and 86 days for 
etirinotecan pegol. Etirinotecan pegol significantly increased median survival in 231-Br 
tumor mice compared to vehicle or conventional chemotherapy, with 40% of mice 








Figure 4.3. Etirinotecan pegol reduces tumor burden in the JIMT-1-Br model 
compared to lapatinib and vehicle.  
(A) Following intracardiac injection of JIMT-1-Br cells and establishment of brain 
metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and 
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean 
BLI signal versus time in JIMT-1-Br mice treated with therapy. Treatment was initiated 
on day 14. Each data point represents mean ± SD (n = 2-10 per time point). Tumor 
burden in etirinotecan pegol-treated mice was significantly lower than lapatinib or 






Figure 4.4. Kaplan-Meier survival curve of JIMT-1-Br mice treated with 
etirinotecan pegol and conventional chemotherapy.  
On day 14 after intracardiac injection of JIMT-1-Br cells, mice were treated with vehicle 
(saline, n = 9), lapatinib (100 mg/kg, n = 9), or etirinotecan pegol (50 mg/kg, n = 10). 
Median survival times were 28 days for vehicle, 29 days for docetaxel, and 34 days for 
etirinotecan pegol. Etirinotecan pegol significantly increased median survival in JIMT-1-
Br tumor mice compared to vehicle or conventional chemotherapy, with 10% of mice 







Figure 4.5. Etirinotecan pegol does not significantly reduce tumor burden in the 
4T1-Br model compared to vehicle.  
(A) Following intracardiac injection of 4T1-Br cells and establishment of brain 
metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and 
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean 
BLI signal versus time in JIMT-1-Br mice treated with therapy. Treatment was initiated 
on day 3. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden 
in etirinotecan pegol-treated mice was not significantly lower than vinorelbine, eribulin, 





Figure 4.6. Kaplan-Meier survival curve of 4T1-Br mice treated with etirinotecan 
pegol and conventional chemotherapy.  
On day 3 after intracardiac injection of 4T-1-Br cells, mice were treated with vehicle 
(saline, n = 9), docetaxel (10 mg/kg, n = 10), vinorelbine (10 mg/kg, n = 8), eribulin (1.5 
mg/kg, n = 10), gemcitabine (60 mg/kg, n = 8), or etirinotecan pegol (50 mg/kg, n = 9). 
Median survival time were 15 days for vehicle, 19 days for docetaxel, 17 days for 
vinorelbine, 16.5 days for eribulin, 28.5 days for gemcitabine, and 16 days for 
etirinotecan pegol. Unlike gemcitabine or docetaxel, tirinotecan pegol did not 
significantly improve median survival compared to vehicle (p > 0.05). Data was analyzed 








Figure 4.7. Accumulation of irinotecan in tumors and normal brain from 14C-etirinotecan pegol.  
(A) A representative sagittal image of a MDA-MB-231-Br brain metastases and corresponding (B) 14C-etirinotecan pegol 
accumulation 24 hours after intravenous administration of radiolabeled etirinotecan pegol. (C) The mean lesion accumulation 




Drug Source Dose Formulation Administration 
Docetaxel SelleckChem 10 mg/kg 5% ethanol, 5% Tween 80, 90% saline IV every 7 days 
Eribulin  
mesylate 
Adooq 1.5 mg/kg 5% ethanol, 15% distilled water, 80% 
saline 





50 mg/kg Saline IV every 7 days 
Gemcitabine SelleckChem 60 mg/kg Saline IP, every 4 days 
Lapatinib ApexBio 100 mg/kg 0.1% Tween 80, 1% 
hydroxypropylmethylcellulose, 
distilled water 
PO twice daily 
Vinorelbine SelleckChem 10 mg/kg Saline IV every 7 days 
Table 4.1. Chemotherapy formulations and dosage schedules for NKTR-102 BCBM.  




 MDA-MB-231-Br JIMT-1-Br 4T1-Br 
Compound IC50 ± SD IC50 ± SD IC50 ± SD 
Docetaxel 0.41 ± 0.2 µM   
Eribulin 3.1 ± 0.2 µM  4.3 ± µM 
Gemcitabine   174 ± nM 
Irinotecan 1 ± 0.11 µM 39 ± µM 12.6 ± µM 
Lapatinib  1.4 ± µM  
SN-38 11.2 ± 2.9 nM 222 ± nM 24.9 ± nM 
Vinorelbine 16.4 ± 11.2 nM  10 ± nM 
Table 4.2. In-vitro cytotoxicity assay of chemotherapy in cancer cell lines.  
5,000 cancer cells per well were treated with increasing concentrations of compound. All 
data represents mean ± SD, n = 96.  
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 MDA-MB-231-Br JIMT-1-Br 4T1-Br 
 Survival 
(Days) 
vs. Vehicle Survival 
(Days) 
vs. Vehicle Survival 
(Days) 
vs. Vehicle 
Docetaxel 39 0.41   18.5 < 0.01* 
Eribulin 40.5 0.54   16.5 0.83 
Gemcitabine 48 0.11   26 < 0.01* 
Irinotecan 42 0.90     
NKTR-102 86 < 0.01* 34 < 0.01* 16 0.80 
Lapatinib   29 0.49   
Vehicle 40  28  16  
Vinorelbine 43 0.93   17 0.52 
Table 4.3. Survival analysis of chemotherapy and vehicle.  
Intracardiac injections resulted in triple negative (231-Br, 4T1) or HER2+ (JIMT-1) breast cancer brain metastases which were 
treated with chemotherapy. NKTR-102 extended median survival by 46 days in the 231-Br model, 6 days in the JIMT-1 




CHARACTERIZATION OF PRECLINICAL PC-9 LUNG CANCER 
BRAIN METASTASES 
5.1 Introduction 
 Lung cancer is the leading cause of cancer death in both men and women 
worldwide. [1] Lung cancer is the most common cause of brain metastases, which is 
often a fatal prognosis due to a lack of curative treatment modalities. [2] There is no one 
universal effective screening tool for lung cancer as there are for other cancer types, such 
as breast cancer or melanoma. [3] The lapse between disease onset and diagnosis allows 
the majority of lung cancer to be metastatic on presentation. Up to 65% of all lung cancer 
patients will eventually develop brain metastases, making lung cancer brain metastases 
(LCBM) a disease with heavy burden. Though certain characteristics are known about 
brain metastases in general, investigation has revealed surprising information about brain 
metastases based on tissue of origin. 
 In 2010, it was discovered that breast cancer brain metastases (BCBM) featured 
increased vascular permeability due to loss of integrity, and that accumulation of 
chemotherapy is increased in metastatic lesions compared to brain parenchyma. [4] This 
permeability was variable within metastases, between the triple negative and HER2+ 
subtypes, and due to the blood-tumor barrier (BTB) restriction of chemotherapy, only 
approximately 10% of brain metastases were reaching cytotoxic concentrations. [4] 
Multiple preclinical studies since have demonstrated that permeability within and 
126 
 
between BCBM are heterogeneous, with the conclusion that more brain-penetrating 
agents must be created, or methods developed to escape the barrier restriction. [5, 6] 
 Characterization of vascular permeability and chemotherapy uptake are yet to be 
performed on LCBM. The two most common types of LCBM are small-cell and non-
small-cell lung cancer, the latter has three prominent mutations: KRAS, EGFR, and 
EML4-ALK. Currently, no FDA-approved targeted therapy exists towards the most 
common KRAS mutation. Within the scope of EGFR, the deletion on exon 19 confers 
sensitivity to targeted inhibitors. Subsequently, the PC-9 cell line bearing the EGFR del 
19 mutation was developed into brain-seeking metastatic lines and studied in the context 
of effects of passive vascular permeability and chemotherapeutic efficacy. 
 Herein, we use the passive permeability marker 14C-aminoisobutyric acid (MW 
103.12), a P-glycoprotein substrate Oregon Green (MW 509.38), and albumin-bound 
vascularity marker indocyanine green (MW 774.96) to study effects of chemotherapy on 
tumor vasculature in the PC-9 model of LCBM. Permeability of these markers was 
studied in vehicle brains and brains treated with cisplatin and etoposide, cisplatin and 
pemetrexed, and the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and osimertinib. 
We observed that the brain-seeking variant of the PC-9 line are more resistant to 
chemotherapy than their parenteral counterparts. Passive permeability of 14C-AIB was 
generally significantly higher in tumor regions compared to non-tumor regions. In 
contrast, there was no significant correlation between tumor size and 14C-AIB 
permeability. OG and ICG fold increases varied between each treatment group and were 
not predictable. Tumor sizes are smaller in treatment groups that extend median survival. 
Lastly, we observed that there was no correlation between survival and tumor size. This 
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is the first paper to illustrate the heterogeneity of tumor distribution and vascular 
permeability of lung-brain metastases, especially in the context of therapeutic treatment. 
5.2 Methods and Materials  
Animals 
 The animal protocol used is the same as in Chapter 3.2.  
Cells 
 The parenteral PC-9 cells were provided by Dr. Lori Hazlehurst’s laboratory, and 
came transduced to display Tomato Red and Firefly luciferase (Luc2=tdT), allowing for 
fluorescence quantification and bioluminescence tracking. The pcDNA3.1(+)/Luc2=tdT 
was a gift from Christopher Contag (addgene plasmid # 32904). Cells were grown in 
RPMI supplemented with 10% fetal bovine serum, 5% penicillin-streptomycin, and 10 
μL/mL of G4918 to ensure selection of transduced cells. Cells were kept at 37C and 5% 
CO2. All cells used for in-vivo and in-vitro experiments were between passages 1-10.  
Stereotactic injection 
 Mice were anesthetized and induced using 2% isoflurane. After placement into a 
stereotactic device (Stoelting), approximately 150,000 PC-9 cells in 100 μL were injected 
into the left ventricle. Bioluminescence verified presence in the brain. Upon termination, 
animals were euthanized and brains were extracted to begin ex-vivo creation of the PC-9 




 The protocol developed by Yoneda et al. was similarly followed to establish the 
PC-9-Br line. [7] After cancer cells were injected and animals became moribund with 
neurological symptoms, they were given 100 mg/ketamine and 8 mg/kg xylazine and 
then euthanized. The brain was removed from the cranium and minced into fine pieces. 
The minces were added to 10 mL of 1.5 mg/mL of collagenase I in DMEM and shaken at 
300 RPM for 1 hour at 37C. The partially-digested mince was passed through a 19G 
syringe to further break up tissue, then strained through a 70 μm cell strainer. The 
collagenase-containing mixture was neutralized with equal amount of DMEM and FBS 
for 10 minutes, then rinsed with 10 mL of PBS. To separate myelin from the cells, 10 mL 
of 25% bovine serum albumin in PBS was added and spun at 2000 to 2200 RPM for 15 to 
20 minutes. Cells were then collected and placed immediately in media with G418 
selection to allow for growth. After 3 days, cells were washed and re-plated for at least 24 
hours prior to re-injection in mice. This process was repeated until the extracted 
population predominantly formed tumors in the brain, which was 6 times for the PC-9 
line.  
Drugs and dosing 
 Cisplatin (5 mg/kg, weekly) and either etoposide (100 mg/kg, days 2 through 5 
after cisplatin administration) or pemetrexed (100 mg/kg, days 3 through 5 after cisplatin 
administration) were selected to represent the most common nonspecific platinum 
doublet therapy given to lung cancer patients. Cisplatin and pemetrexed were dissolved in 
saline, and etoposide was dissolved in 5% DMSO, 5% Tween 80, and 90% saline prior to 
intravenous dosing. Gefitinib (6.25 mg/kg), afatinib (30 mg/kg), and osimertinib (25 
mg/kg), representing three generations of EGFR inhibitors, were dosed orally once daily, 
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and were formulated in 1% DMSO, 29% polyethylene glycol 400, and 70% distilled 
water. All chemotherapy was purchased from SelleckChem. Drugs, formulations, and 
dosing regimens are summarized in Table 5.1. 
Brain extraction 
 Upon reaching survival endpoints, mice were anesthetized and given tail vein 
injections of 150 μg of Oregon Green (OG) dissolved in PBS, along with 10 μCi of 14C-
aminoisobutyric acid (14C-AIB). Following a 10-minute circulation, the descending aorta 
and inferior vena cava were clamped off. A solution of 6 mg of indocyanine green (IR-
820, ICG) bound to 0.27% bovine serum albumin (270 mg in 10 mL) was perfused 
through the left ventricle at 5 mL/min to provide a washout. Brains were then rapidly 
removed and submerged in isopentane (-80oC) and stored at -20oC prior to tissue slicing 
and visualization. 
Tissue processing and quantification 
 Brains were mounted and 20 μm slices were created with the Leica CM3050S 
cryotome (Leica Microsystems, Wetzlar, Germany), which were transferred to charged 
microscope slides. Each slide contains 3 slices for a total of approximately 120 slices per 
brain. Brain slice fluorescence was acquired using a stereomicroscope (Olympus 
MVX10; Olympus, Center Valley, PA) equipped with a 0.5 NA 2X objective and a 
monochromatic cooled CCD scientific camera (Retiga 4000R, QIMaging, Surrey, BC, 
Canada). Tomato Red fluorescence was imaged using a DsRed sputter filter 
(excitation/band λ 545/25nm, emission/band λ 605/70nm and dichromatic mirror at λ 
565nm) (Chroma Technologies, Bellows Falls, VT), Oregon Green using an ET-GFP 
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sputter filter (excitation/band λ 470/40nm, emission/band λ 525/50nm and dichromatic 
mirror at λ 495nm) (Chroma Technologies, Bellows Falls, VT), and ICG using a Cy7 
sputter filter (excitation/band λ 710/75nm, emission/band λ 810/90nm and dichromatic 
mirror at λ 760nm) (Chroma Technologies, Bellows Falls, VT). Fluorescence was 
captured and analyzed using CellSens (Olympus) software. OG and ICG fluorescence 
intensity increases were determined by sum intensity per unit of metastatic lesion area 
relative to non-tumor brain regions.  
Quantitative autoradiography 
 Fluorescence imaging slides and 14C-AIB slides were placed in quantitative 
autoradiography (QAR) cassettes (FujiFilm Life Sciences, Stanford, CT) along with 14C 
autoradiographic standards (American Radiochemicals, St. Louis, MO). A phosphor 
screen (FujiFilm Life Sciences, 20 × 40 super-resolution) was placed with the slides and 
standards and allowed to develop for 21 days. QAR phosphor screens were developed in 
a high-resolution phosphor-imager (GE Typhoon FLA 7000, Uppsala, Sweden) and 
converted to digital images, which were then calibrated to 14C standards and analyzed 
using MCID Analysis software (InterFocus Imaging LTD, Linton, Cambridge, England). 
Metastases permeability fold-changes were calculated based on 14C-AIB signal intensity 
within confirmed metastases locations (determined using cresyl violet and Tomato Red 
fluorescence intensity overlays) relative to non-tumor brain 14C-AIB signal intensity. 
Tumor Staining 
Tissue sections were processed as described above. After allowing tissues to 
become adherent to charged slides overnight, slides were briefly dipped in PBS. Staining 
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was performed using 0.1% cresyl violet acetate (Sigma-Aldrich, St. Louis, MO) (2 
minutes) followed by briefly rinsing in tap water. Sections were cleared in 70% ethanol 
(15 seconds), 95% ethanol (30 seconds), 100% ethanol (30 seconds), respectively. 
Images were obtained with a 2x objective on the Olympus MVX microscope. 
Cytotoxicity assays 
 Following the creation of PC-9-Br, in vitro MTT toxicity was performed to 
determine potential differences in drug sensitivity between the parenteral line and the 
brain-seeking line. 5,000 cells per well were plated in a 96-well plate and allowed to 
attach overnight in an incubator. The next day, after aspiration, drugs were added to 
wells. For all cytotoxicity assays, drugs were dissolved in DMSO or media to create a 10 
mM stock, then further diluted in media to create standard concentrations. If drugs were 
dissolved in DMSO, similar amounts of DMSO were added to control wells. Plates were 
then incubated for 72 hours. 50 μL of a 1 mg/mL solution of MTT was then added per 
well and incubated for another 2 hours. Wells were then aspirated and 100 μL of DMSO 
was added per well and gently shaken for 1 hour to solubilize formazan crystals. Plates 
were then read at 570 nM on the Synergy Hybrid 1 plate reader. Fluorescence values 
were converted to percentages based on the control average and plotted against a log-
scale of drug concentration.  
Statistics 
 All statistics were performed on GraphPad Prism software. XY plots were 
analyzed by linear regression. Median and interquartile ranges are used for permeability 
changes and size of metastases. A D’Agostino and Pearson omnibus test was performed 
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and determined a non-Gaussian distribution of data. Statistical analysis of permeability 
and size was performed using the non-parametric Kruskal-Wallis test followed by Dunn's 
multiple comparison test. Animal median survival data was analyzed using the log-rank 
test. Significance for all tests was defined as p < 0.05.  
5.3 Results 
The sixth round of PC-9 injections predominantly seeds the brain and has 
shorter survival than the parenteral line 
Using the method developed by Yoneda et al, PC-9 cells were injected and 
extracted through six rounds in female nude mice. The cells from this sixth round are 
“brain-seeking” and the line is now termed PC-9-Br. Fig. 5.1 shows the distribution of 
the sixth round of PC9 injections (A), stills from a 3D reconstruction of a mouse with 
brain tumor (B-E), and the survival curve of the parenteral and brain-seeking PC-9 line 
(F). While the median survival was 61.5 days (n = 2) in the parenteral line, the median 
survival for the brain-seeking line is significantly shorter at 45.5 days (n = 4) (p < 0.05). 
Oregon Green is a substrate for P-glycoprotein efflux 
In order to determine if OG is a P-glycoprotein substrate, a Fluoroblock transwell 
experiment featuring increasing concentrations of OG and a Texas Red dextran 3kDa 
control were performed. A normalized time-lapse of OG (Fig. 5.2A) revealed increased 
concentrations when given the P-gp inhibitor tariquidar 1 µM, while a time-lapse of 
Texas Red dextran (Fig. 5.2A) showed no significant changes through time when 
exposed to tariquidar. For comparison, (Fig. 5.2B) raw fluorescence units show similar 
findings. A comparison of OG and 14C-AIB in the drug models (Fig. 5.2C-H) reveals 
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similar results to the effects of rhodamine 123 and 14C-AIB in BCBM models, indicating 
that OG is effluxed by tumors due to P-glycoprotein. [8] 
PC-9-Br creates numerous, widespread, and various sized brain metastases 
To view the tumor and vascular distribution of PC-9-Br, an intracardiac perfusion 
of OG was performed on a vehicle-treated PC-9-Br mouse. After extraction, the brain 
was placed on a glass petri dish and imaged on the Olympus MVX. Fig. 5.3 presents the 
metastatic lesions and cerebral vasculature from the frontal cortex to the cerebellum. 
Bioluminescence (Fig. 5.3A) and fluorescence (Fig. 5.3B) outline the location of tumors 
within the brain. Four coronal slices were taken 800 – 1600 μm apart, which are depicted 
in a brain atlas (Fig. 5.3 C1-F4). 
The PC-9-Br line forms spinal metastases due to ventricular infiltration 
While the majority of PC-9-Br tumor burden is within the brain, vertebral lesions 
often develop. This is an expected distribution of most brain-seeking tumor lines, with 
spinal cord affinity as a theorized mechanism. [9] Fig. 5.4 shows a brain slice of a vehicle 
mouse with a tumor on the periphery of the right lateral ventricle, with the choroid plexus 
separating the tumor into two sections. On bioluminescence imaging, a spinal lesion is 
noted in the mouse that this brain was taken from (Fig. 5.4A). Within the ventricle, tumor 
cells are seen co-opting the choroid plexus, which contains OG (Fig. 5.4B-D).  
 PC-9-Br are less sensitive to conventional and targeted lung chemotherapy than 
parenteral PC-9 in-vitro 
 A cytotoxic assay was performed to evaluate the chemotherapeutic sensitivity of 
the parenteral and brain-seeking PC9 lines. In the parenteral line, SN-38 sensitivity is 7 
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nM, more than two orders of magnitude lower than the 6 µM SN-38 sensitivity of the 
brain-seeking line. The etoposide sensitivity of the parenteral line (408 nM) is more than 
100-fold lower than in PC-9-Br (6.4 µM). Pemetrexed sensitivity is modestly higher in 
the PC-9-Br (512 nM) compared to PC-9-P (391 nM), while cisplatin sensitivity is 
slightly lower (593 nM vs. 669 nM, respectively). This trend is seen again in targeted 
tyrosine kinase inhibitors. While the parenteral line is sensitive in the femtomolar range 
to erlotinib, gefitinib, afatinib, and osimertinib, the PC-9-Br sensitivities are in the 
nanomolar range, more than a 10-fold difference. A representative IC50 curve 
demonstrating the reduced sensitivity of PC-9-Br to PC-9-P is depicted in Fig. 5.5. The 
PC-9-Br are more sensitive to tyrosine kinase inhibitors than conventional lung 
chemotherapy agents and SN-38 (Table 5.1).  
Vehicle treated tumors are significantly more permeable to 14C-AIB and have 
higher OG but not ICG fluorescence intensity than non-tumor regions 
As animals became moribund with neurological symptoms, we sought to 
determine the extent and differences of passive permeability, P-gp efflux, and vascularity 
of control and drug-treated tumors via use of three different molecular weight markers, 
starting with vehicle (Fig. 5.6). Passive permeability changes in vehicle metastatic lesions 
ranged from 0.4505 to 38.39-fold over normal brain with a median (IQR) fold change of 
3.254 (1.928 – 5.971) for 14C-AIB (Fig. 5.6F), which were significantly higher than non-
tumor regions (p < 0.01). For OG, fluorescence intensity ranged from 0.9974 to 1.271-
fold with a median (IQR) fold change of 1.007 (1.004 – 1.013), which was significantly 
higher than non-tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 
0.9866 to 1.053-fold with a median (IQR) fold change of 1.0 (0.9953 – 1.002), which was 
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not significantly higher than non-tumor regions (p > 0.05). No correlation was observed 
(r2 < 0.02) for OG, ICG, or 14C-AIB passive permeability and metastasis size (Fig. 5.6G). 
 Cisplatin-etoposide treated tumors are significantly more permeable to 14C-
AIB, and have higher OG and ICG fluorescence intensity than non-tumor regions 
After seeing a positive trend in vehicle tumors, we turned our sights on 
characterizing tumors treated with conventional lung therapy, starting with the cisplatin 
doublet therapy with etoposide (Fig. 5.7). Passive permeability changes in cisplatin-
etoposide metastatic lesions ranged from 0.3021 to 18.55-fold over normal brain with a 
median (IQR) fold change of 1.231 (0.8541 – 2.077) for 14C-AIB (Fig. 5.7F), which was 
significantly higher than non-tumor regions (p < 0.01). For OG, fluorescence intensity 
ranged from 0.9891 to 1.190-fold with a median (IQR) fold change of 1.020 (1.007 – 
1.037), which was significantly higher than non-tumor regions (p < 0.01). For ICG, 
fluorescence intensity ranged from 0.9597 to 1.078-fold with a median (IQR) fold change 
of 0.9885 (0.9810 – 1.001), which was significantly higher than non-tumor regions (p > 
0.01). There was a no correlation (r2= 0.07) to changes in 14C-AIB permeability and 
lesion size, while a moderate correlation was observed (r2 = 0.42) for OG but not ICG (r2 
= 0.03) fluorescence intensity and metastasis size in the cisplatin-etoposide model (Fig. 
5.7G). 
Cisplatin-pemetrexed treated tumors are significantly more permeable to 14C-
AIB and have higher OG but not ICG fluorescence intensity than non-tumor regions 
After seeing a positive trend in the cisplatin-etoposide doublet therapy, we turned 
our sights on characterizing the cisplatin-pemetrexed doublet therapy (Fig. 5.8). Passive 
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permeability changes in cisplatin-pemetrexed brain tumors ranged from 0.1601 to 24.83-
fold over normal brain with a median (IQR) fold change of 4.235 (1.681 – 7.046) for 14C-
AIB (Fig. 5.8F), which was significantly higher than non-tumor regions (p < 0.01). For 
OG, fluorescence intensity ranged from 0.0652 to 1.565-fold with a median (IQR) fold 
change of 1.049 (1.010 – 1.144), which was significantly higher than non-tumor regions 
(p < 0.01). For ICG, fluorescence intensity ranged from 0.5926 to 4.490-fold with a 
median (IQR) fold change of 0.9991 (0.9941 – 1.005), which was not significantly higher 
than non-tumor regions (p > 0.05). There was a moderate correlation (r2= 0.44) in 14C-
AIB permeability and lesion size. No correlation was observed for OG (r2 = 0.12) or ICG 
(r2 = 0.03) fluorescence intensity and metastasis size in the cisplatin-pemetrexed model 
(Fig. 5.8G). 
Gefitinib treated tumors are significantly more permeable to 14C-AIB and have 
higher OG but not ICG fluorescence intensity than non-tumor regions 
Aside from platinum doublet therapy, EGFR-mutated tumors can be treated with 
targeted tyrosine kinase inhibitors. Gefitinib represents a first-generation targeted EGFR-
inhibitor (Fig. 5.9). Passive permeability changes in gefitinib brain tumors ranged from 
0.7222 to 12.94-fold over normal brain with a median (IQR) fold change of 4.537 (2.707 
– 8.20) for 14C-AIB (Fig. 5.9F), which was significantly higher than non-tumor regions 
(p < 0.01). For OG, fluorescence intensity ranged from 0.9747 to 1.352-fold with a 
median (IQR) fold change of 1.028 (1.006 – 1.066), which was significantly higher than 
non-tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9985 to 
1.070-fold with a median (IQR) fold change of 1.030 (1.002 – 1.042), which was not 
significantly higher than non-tumor regions (p > 0.05). There was a moderate correlation 
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(r2= 0.33) to changes in 14C-AIB permeability and lesion size. No correlation was 
observed for OG or ICG (r2 < 0.03) fluorescence intensity and metastasis size in the 
gefitinib model (Fig. 5.9G). 
Afatinib treated tumors are significantly more permeable to 14C-AIB, and have 
higher OG and ICG fluorescence intensity than non-tumor regions  
Afatinib represents a second-generation EGFR-tyrosine kinase inhibitor (Fig. 
5.10). Passive permeability changes in afatinib brain tumors ranged from 0.2958 to 
7.936-fold over normal brain with a median (IQR) fold change of 1.315 (0.8746 – 2.197) 
for 14C-AIB (Fig. 5.10F), which was significantly higher than non-tumor regions (p < 
0.01). For OG, fluorescence intensity ranged from 0.9854 to 1.080-fold with a median 
(IQR) fold change of 1.011 (1.003 – 1.021), which was significantly higher than non-
tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9975 to 1.055-
fold with a median (IQR) fold change of 1.001 (0.9957 – 1.007), which was also 
significantly higher than non-tumor regions (p < 0.05). There was a no correlation (r2 < 
0.01) to changes in 14C-AIB, OG, or ICG passive permeability and metastasis size in the 
afatinib model (Fig. 5.10G). 
Osimertinib treated tumors are significantly more permeable to 14C-AIB, and 
have higher OG and ICG fluorescence intensity non-tumor regions  
Osimertinib represents a third-generation EGFR-tyrosine kinase inhibitor (Fig. 
5.11). Passive permeability changes in osimertinib brain tumors ranged from 0.1618 to 
8.891-fold over normal brain with a median (IQR) fold change of 1.950 (1.328 – 3.033) 
for 14C-AIB (Fig. 5.11F), which was significantly higher than non-tumor regions (p < 
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0.01). For OG, fluorescence intensity ranged from 0.9703 to 1.375-fold with a median 
(IQR) fold change of 1.077 (1.041 – 1.138), which was significantly higher than non-
tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9862 to 1.054-
fold with a median (IQR) fold change of 1.006 (1.002 – 1.020), which was also 
significantly higher than non-tumor regions (p < 0.01). There was a no correlation (r2 < 
0.05) to changes in 14C-AIB, OG, or ICG passive permeability and metastasis size in the 
osimertinib model (Fig. 5.11G). 
14C-AIB permeability is associated with chemotherapeutic efficacy 
A comparison of fold increases of OG and ICG fluorescence increases across drug 
treated groups reveals that most tumor regions are similar to control areas (Fig. 5.12). In 
comparison, 14C-AIB passive permeability in tumors is much higher, ranging from 3- to 
12-fold above non-tumor regions. Lower 14C-AIB fold increases over control areas are 
found in cisplatin-etoposide, afatinib, and osimertinib-treated groups, which are the only 
treatment groups to increase survival. 
 PC-9-Br tumor size and number are moderately correlated with survival  
After survival endpoints were reached, brains were sliced and analyzed for tumor 
count. A D'Agostino & Pearson omnibus normality test showed no compounds tested 
displayed a Gaussian distribution, so median and interquartile range column statistics 
were calculated (Table 5.2). Of 114 vehicle tumors, median tumor size was 0.1844 mm2 
(IQR: 0.1129 – 0.3097) with a 42-day median survival. Of 117 cisplatin-etoposide 
tumors, median tumor size was 0.1093 mm2 (IQR: 0.0533 – 0.2384) with a 51.5-day 
median survival. Of 110 cisplatin-pemetrexed tumors, median tumor size was 0.2492 
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mm2 (IQR: 0.1305 – 0.4054, with a 45-day median day survival. Of 34 gefitinib tumors, 
median tumor size was 0.5530 mm2 (IQR: 0.2868 – 0.6787), with a 48-day median 
survival. Of 85 afatinib tumors, median tumor size was 0.1459 mm2 (IQR: 0.0687 – 
0.2809) with a 73-day median survival. Of 56 osimertinib tumors, median tumor size was 
0.1293 mm2 (IQR: 0.0629 – 0.2125), with a 73-day median survival. Linear regression of 
median metastases size and days of survival on chemotherapy produced an r2 of 0.3461, 
while a linear regression of tumor number and survival produced an r2 of 0.22.  
 Distribution of PC-9-Br tumors follow surface area and blood flow patterns 
 After slicing and characterizing dye fold increases, we sought to determine the 
distribution of tumors within the brain (Fig. 5.13). The majority of tumors occur in the 
cortex regardless of treatment (Fig. 5.13J). Blood flow is approximately 1 mL/g/min in 
these mouse regions, and so the plot of tumors based on brain blood flow (Fig. 5.13K) 
resembles that of total number of tumors (Fig. 5.13J). Gefitinib was observed to have the 
lowest number of tumors of the brains analyzed. 
5.4 Discussion 
As tumors grow, their requirement for enhanced nutrition stimulates the formation of 
new vasculature that joins nearby blood vessels in a process known as angiogenesis. [10] 
As vessels form, they are initially immature and compromised; the resultant loss of 
barrier integrity allows passive permeation of formerly restricted substances into tumor 
and brain parenchyma. [11]  
Typical chemotherapy sizes range from a molecular weight of 300 (nucleotide 
analogues) to more than 100,000 (antibodies). Cisplatin (300 Da), etoposide (589 Da), 
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pemetrexed (472 Da), gefitinib (447 Da), afatinib (486 Da), and osimertinib (500 Da) are 
clinically used therapeutics in the treatment of lung cancer. The size range of these agents 
are encompassed by 14C-AIB (103 Da) and the P-gp substrate OG (509 Da), with 
albumin-bound ICG representing antibody size and vascularity. [12, 13] 
To create a brain metastatic model, two main methods exist: intracardiac and 
intracarotid injections. [14] While intracarotid injections deliver cancer cells directly to 
the brain compared to intracardiac injections which allow cancer cells to circulate 
throughout the arterial system, intracarotid injections are much more invasive and time-
consuming, and often have similar results to intracardiac injections. [15] Our method of 
injection occasionally leads to mandibular metastases (S1) which are often found in 
preclinical brain metastases models as well as clinical settings. [16-18] Of note, 
ventricular infiltration and development of spinal metastases have been noted in BCBM 
models as well. [19, 20] 
The PC-9 cell line is commonly utilized in preclinical lung cancer research to 
evaluate the effects of chemotherapy in an EGFR-mutant model. [21-23] PC-9 are 
sensitive to first generation (gefitinib) and second generation (afatinib) tyrosine kinase 
inhibitors, and can be induced to form the T790M mutation which often leads to drug 
resistance and relapse in the clinical setting. [24, 25] Osimertinib, a third generation 
inhibitor, overcomes the T790M mutation and is used when resistance to first or second 
generation inhibitors forms. Non-T790M mutated PC-9 cells are also sensitive to 
osimertinib, which is why it was included in our trial. [21, 26]  
Similar to preclinical breast cancer brain metastases (BCBM), PC-9-Br tumors are 
generally less than 1 mm2, however PC-9-Br are far less permeable to both 14C-AIB and 
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similarly-sized fluorescent markers. [27] The median permeability of 14C-AIB in LCBM 
ranges between 1.2- to 4.5-fold above control regions, while in BCBM the median 
permeability ranges between 2.1 to 12-fold above control regions. [27] Both BCBM and 
LCBM contrast with primary glioblastoma, whose lesions are much larger and much 
more permeable to 14C-AIB, with rates of transfer that near water diffusion. [28]  
The effect of tumor size and survival is not yet fully understood. A preclinical model 
of BCBM showed that larger tumor sizes were associated with higher median survival. 
[27] In contrast, smaller median tumor sizes (≤ 1.5 mm2) were associated with longer 
median survival in our LCBM model. These smaller median tumor sizes were also linked 
with therapy that extended median survival, thus portraying a therapy-size-survival 
interaction. Our LCBM findings correspond with targeted inhibitors showing reduction of 
brain metastases size in the clinical setting. [29, 30]  
Much like the BCBM models, the PC-9-Br line expresses the efflux pump P-
glycoprotein. [8] In this model, rhodamine 123 (Rh123) was perfused and compared 
against 14C-AIB fold changes in tumor regions and control areas. Much like our OG 
results, Rh123 values ranged between 0.9 and 1.5-fold above non-tumor regions, 
indicating that P-gp exists at the tumor barrier and though some dye does passively 
permeate into tumor, OG is also a substrate for P-gp-mediated efflux. 
5.5 Conclusion 
The EGFR-mutant PC-9-Br creates many scattered brain metastases, most of 
which are ≤ 1.0 mm2. These tumors are similarly permeable to breast cancer brain 
metastases and have active P-glycoprotein to efflux chemotherapy. Conventional 
chemotherapy such as cisplatin, etoposide, and pemetrexed are not as effective in 
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increasing median survival as targeted EGFR inhibitors, especially second (afatinib) and 
third (osimertinib) generation agents. Tumors treated with these agents have smaller 
tumor sizes and lower 14C-AIB permeability. 
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Figure 5.1: Distribution and survival of the brain-seeking PC-9 cell line.  
(A) Visualization of tumor burden in athymic nude female mice injected with PC-9-Br cells. The majority of tumor burden is 
within the brain, with a smaller amount of vertebral metastases. (B-E) Micro-CT reconstruction of a mouse with a PC-9-Br 
tumor shows the anatomical location of the tumor. (F) Median survival for the PC-9-P parenteral line is 61.5 days (n = 2), 
which is significantly reduced in brain-seeking PC-9-Br line (45.5 days, n = 4) (p < 0.05).  
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Figure 5.2. Oregon Green is a P-glycoprotein substrate.  
(A) A Fluoroblock transwell experiment of Oregon Green ± tariquidar 1µM and known 
non-P-gp substrate Texas Red Dextran 3kDa ± TQ shows OG fluorescence increases over 
time when exposed to TQ, with data normalized for ease of comparison. (B) Unadjusted 
data is shown for comparative purposes. (C) Vehicle, (D) C+E, (E) C+P, (F) Gefitinib, 
(G) Afatinib, and (H) Osimertinib feature similar OG permeability ratios to known P-gp 




Figure 5.3. Distribution of brain metastases in PC-9-Br.  
(A) Luciferin bioluminescence shows the large PC-9-Br tumor burden. (B) Fluorescence imaging contrasts the Oregon Green-
perfused vasculature and the distribution of Tomato Red-expressing tumors. Four numbered slices (1 = # mm; 2 = # mm; 3 = # 
mm; 4 = # mm) correspond to the coronal sections (C-F). (C) Visualization of brain metastases based on cresyl violet staining. 
(D) Tomato Red tumors accurately represent tumor burden confirmed by cresyl violet staining. (E) Oregon Green highlights 
normal and disrupted vasculature in tumor brain. (F) An overlay of Oregon Green and Tomato Red depicts tumor environment 




Figure 5.4. Ventricular infiltration leads to spinal tumor burden.  
(A) Bioluminescence data shows a large tumor burden in the brain with smaller spinal 
lesions. The brain was extracted, sliced, and imaged. (B) Fluorescence imaging shows a 
Tomato Red tumor invading the lateral ventricle. (C and D) A tumor mass and individual 





Figure 5.5. PC-9-Br is less sensitive to chemotherapy compared to the parenteral 
line.  
A representative IC50 curve depicts the reduced etoposide sensitivity of PC-9-Br (6.4 µM) 




Figure 5.6. Permeability changes of PC-9-Br treated with vehicle.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 3.3 
C4) of vehicle-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor 
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB auto-
radiographic data to quantify permeability increases. (F) The median and interquartile 
ranges for fold-increases of passive permeability markers in 114 tumors over control 
regions. For vehicle brains, tumors were significantly more permeable to OG and 14C-
AIB (p < 0.05), but not ICG (p > 0.05). (G) The fold increases of OG, ICG, or 14C-AIB 
were not correlated with metastases size (r2 < 0.02). For all depicted brain slices, tumor 
regions are outlined while control areas are squares. Scale bar = 1 mm. 
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Figure 5.7. Passive permeability changes of PC-9-Br treated with cisplatin-
etoposide.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3 
C1) of cisplatin-etoposide-treated PC-9-Br tumors, with (B) corresponding Tomato Red 
tumor fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB 
autoradiographic data to quantify P-gp, vascularity, and permeability increases, 
respectively. (F) The median and interquartile ranges for fold-increases of dyes in 117 
tumors over control regions. For cisplatin-etoposide-treated brains, tumors were 
significantly more permeable 14C-AIB and had more P-gp and vascularity than control 
regions (p < 0.05). (G) The fold increases of OG, ICG, or 14C-AIB were not correlated 
with metastases size (r2 < 0.02). For all depicted brain slices, tumor regions are outlined 
while control areas are squares. Scale bar = 1 mm. 
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Figure 5.8. Passive permeability changes of PC-9-Br treated with cisplatin-
pemetrexed.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3 
C3) of cisplatin-pemetrexed-treated PC-9-Br tumors, with (B) corresponding Tomato Red 
tumor fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB 
autoradiographic data to quantify P-gp, vascularity, and permeability increases, 
respectively. (F) The median and interquartile ranges for fold-increases of passive 
permeability markers in 96 tumors over control regions. For cisplatin-pemetrexed-treated 
brains, tumors were significantly more permeable to 14C-AIB and had more P-gp effects 
(p < 0.05), but not vascularity (p > 0.05). (G) While the OG intensity had a modest 
correlation with mm2 (r2 = 0.42), ICG and 14C-AIB were not correlated with metastases 
size (r2 < 0.15). For all depicted brain slices, tumor regions are outlined while control 
areas are squares. Scale bar = 1 mm. 
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Figure 5.9. Passive permeability changes of PC-9-Br treated with gefitinib.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 3.3 
C2) of gefitinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor 
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB 
autoradiographic data to quantify P-gp, vascularity, and permeability increases, 
respectively. (F) The median and interquartile ranges for fold-increases of passive 
permeability markers in 34 tumors over control regions. For gefitinib-treated brains, 
tumors were significantly more permeable 14C-AIB and had more P-gp activity (p < 
0.05), but not vascularity (p > 0.05). (G) While the permeability-fold increases of 14C-
AIB had a modest correlation with mm2 (r2 = 0.33), OG and ICG were not correlated with 
metastases size (r2 < 0.13). For all depicted brain slices, tumor regions are outlined while 
control areas are squares. Scale bar = 1 mm. 
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Figure 5.10. Passive permeability changes of PC-9-Br treated with afatinib.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3 
C2) of afatinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor 
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB 
autoradiographic data to quantify P-gp, vascularity, and permeability increases, 
respectively. (F) The median and interquartile ranges for fold-increases of passive 
permeability markers in 85 tumors over control regions. For afatinib-treated brains, 
tumors were significantly more permeable 14C-AIB and had more P-gp activity and 
vascularity (p < 0.05). (G) The fold increases of OG, ICG, or 14C-AIB were not 
correlated with metastases size (r2 < 0.01). For all depicted brain slices, tumor regions are 
outlined while control areas are squares. Scale bar = 1 mm. 
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Figure 5.11. Passive permeability changes of PC-9-Br treated with osimertinib.  
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3 
C4) of osimertinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor 
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB 
autoradiographic data to P-gp, vascularity, and permeability increases, respectively. (F) 
The median and interquartile ranges for fold-increases of passive permeability markers in 
56 tumors over control regions. For osimertinib-treated brains, tumors were significantly 
more permeable to 14C-AIB and had more P-gp activity and vascularity (p < 0.05). (G) 
The fold increases of OG, ICG, or 14C-AIB were not correlated with metastases size (r2 < 
0.05). For all depicted brain slices, tumor regions are outlined while control areas are 




Figure 5.12. Comparison of passive permeability between PC-9-Br treatment 
groups.  
PC-9 tumors are more permeable to the small 14C-AIB markers than non-tumor areas. 
The reduction of 14C-AIB permeability in cisplatin-etoposide, afatinib, and osimertinib 
groups compared to vehicle or cisplatin-pemetrexed groups is linked with an increase in 
median survival. All data represents median and interquartile ranges. AFT: afatinib; C-E: 





Figure 5.13. Distribution of PC-9-Br tumors.  
Representative slices of (A) anterior, (D) middle, and (G) posterior slices from the Allen 
mouse brain atlas. Colors represent different regions of the brain. These correspond with 
representative (B) anterior, (E) middle, and (H) posterior cresyl violet slices of brains 
with PC-9-Br tumors. Color outlines correspond with atlas brain regions. Tomato red 
tumors of (C) anterior, (F) middle, and (I) posterior slices are similarly outlined with 
color. (J) A plot of the total number of tumors based on area of the brain in all treated 
brains. (K) A plot of the number of tumors based on surface area. (L) A plot of the 
number of tumors based on blood flow. Median data is plotted with colors representing 
different treated groups. 
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Supplemental Figure 5.1. Mandibular metastases in the PC-9-Br line.  
Multiple mandibular metastases are present along with intracranial metastases 
characteristic of the PC-9-Br line. This distribution is seen in multiple brain-seeking 




Compound IC50 ± SD IC50 ± SD 
BEACON AGENTS 
Gemcitabine   
Docetaxel  0.2 nM 
Eribulin  20.3 nM 
Vinorelbine  7.1 nM 
SN-38 7.7 ± 39 nM 6 ± 0.1 µM 
CONVENTIONAL LUNG CHEMOTHERAPY AGENTS 
Cisplatin  669 ± 653 nm 593 ± 550 nm 
Etoposide 408 ± 123 nm 6.4 ± 0.4 µM 
Pemetrexed 391 ± 346 nm 512 ± 590 nm 
EGFR-TYROSINE KINASE INHIBITOR AGENTS 
Erlotinib < 100 fM 514.2 ± 100 nm 
Gefitinib < 100 fM 41.5 ± 9.3 nm 
Afatinib < 100 fM 5.2 ± 2.1 nm 
Osimeritinib < 100 fM 4.5 ± 1.9 nm 
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Table 5.1. In-vitro chemotherapeutic sensitivity comparisons of the parenteral and 
brain-seeking PC-9 line.  
MTT assays show that the parenteral cell lines are generally more chemosensitive than 




Therapy n Survival (days) median size  
(mm2) 
IQR (mm2) 
Vehicle 114 42 0.1844 0.1129 – 0.3097 
Cisplatin- 
Etoposide 
117 51.5 0.1093 
0.0533 – 0.2384 
Cisplatin- 
Pemetrexed 
96 45 0.2492 
0.1305 – 0.4054 
Gefitinib 34 48 0.5530 0.2868 – 0.6787 
Afatinib 85 73 0.1459 0.0687 – 0.2809 
Osimertinib 56 73 0.1293 0.0629 – 0.2125 
 
Table 5.2. Sizes of PC-9-Br tumors based on drug treatment.  
Treatment groups that extended median survival significantly beyond vehicle (cisplatin-




 14C-AIB fold increase 
Therapy Median IQR r2 vs. size 
Vehicle 3.254 1.928 – 5.971 0.014 
Cisplatin-
Etoposide 
1.231 0.8541 – 2.077 0.068 
Cisplatin-
Pemetrexed 
4.235 1.681 – 7.046 0.444 
Gefitinib 4.537 2.707 – 8.200 0.325 
Afatinib 1.315 0.8746 – 2.197 0.004 
Osimertinib 1.950 1.328 – 3.033 0.004 
 
Table 5.3. 14C-AIB fold permeability is less in groups that improve median survival. 
In therapy that does not improve median survival (vehicle, cisplatin-pemetrexed, and 
gefitinib), 14C-AIB increases are higher than those that do improve median survival 





 OG fold increase 
Therapy Median IQR r2 vs. size 
Vehicle 1.007 1.004 – 1.013 0.001 
Cisplatin-
Etoposide 
1.020 1.007 – 1.037 0.420 
Cisplatin-
Pemetrexed 
1.049 1.010 – 1.144 0.123 
Gefitinib 1.028 1.006 – 1.066 0.030 
Afatinib 1.011 1.003 – 1.021 0.003 
Osimertinib 1.077 1.041 – 1.138 0.001 
Table 5.4. Oregon Green fluorescence intensity does not correlate with median 
survival improvement. 




 ICG fold increase 
Therapy Median IQR r2 vs. size 
Vehicle 1.000 0.9953 – 1.002 < 0.001 
Cisplatin-Etoposide 0.9885 0.9810 – 1.001 0.031 
Cisplatin-Pemetrexed 0.9991 0.9941 – 1.009 0.030 
Gefitinib 1.030 1.002 – 1.042 0.021 
Afatinib 1.001 0.9957 – 1.007 0.013 
Osimertinib 1.006 1.002 – 1.020 0.042 
 
Table 5.5. ICG fluorescence intensity is similar in all treatment groups. 





EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THE PC-9 
PRECLINICAL LUNG CANCER METASTASES MODEL 
6.1 Introduction 
Lung cancer is the second-most commonly diagnosed cancer in the United States, 
and is the most common cause of cancer death worldwide. [1, 2] It is estimated that more 
than 200,000 new cases of lung cancer will be diagnosed and more than 150,000 cancer 
deaths in the United States in 2018. [2] The average age of diagnosis is 70, while the 
median age of death is 72. The short time from diagnosis to death may be due to the 
advanced stage on presentation. [3]  
Lung cancer metastasizes to the brain in approximately 10 to 30% of patients and 
is responsible for the majority of brain metastases. [4] The propensity to form brain 
metastases is also influenced by lung cancer subtype. Approximately 85% of lung cancer 
are non-small cell lung carcinoma (NSCLC) with small-cell lung carcinoma (SCLC) 
comprising the rest. [5] SCLC presents with brain metastases in 20% of patients, forming 
in 80% within 2 years of diagnosis. [6] Adenocarcinoma, the most common subtype of 
NSCLC, presents with brain metastases in 10% of patients, forming in 40% throughout 
illness progression. [3] Within adenocarcinoma, the most common mutation is KRAS, 
followed by EGFR and EML4-ALK translocation. Targetable drugs exist for EGFR and 
EML4-ALK, but not for KRAS.  
Therapeutic options in the treatment of lung cancer brain metastases (LCBM) 
include surgical resection, stereotactic radiosurgery, whole brain radiotherapy, and 
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chemotherapy. [7] Even when used in combination, these options rarely improve survival 
to over 12 months [8] and are thus often palliative. Incremental improvements have been 
made in treating brain metastases, especially in creating targeted agents and repurposing 
nonspecific chemotherapy. The presence of the blood-brain barrier (BBB) and blood-
tumor barrier (BTB) can significantly hinder penetration of chemotherapeutic agents into 
both tumor and brain tissue. [9] 
The BBB consists of a physical barrier of vascular endothelial cells linked 
together by tight junctions, enzymes such as phosphatases to degrade substances, and 
efflux transports actively restricting molecular entry into the brain, all surrounded by 
astrocytic foot processes performing similar activities. [10] In the BTB, immature 
vasculature structure leads to increased permeability and though drug permeation is 
enhanced, the magnitude of enhancement often falls below therapeutic amounts required 
for efficacy. [9]  
Due to its prevalence in LCBM and in vitro sensitivity to SN-38, the EGFR-
mutant PC-9 cell line was created into a brain-seeking line and tested for preclinical 
survival efficacy of NKTR-102 against BEACON-agents, conventional lung 
chemotherapy, and targeted EGFR inhibitors. Herein, we report that NKTR-102 did not 
reduce tumor burden or improve survival significantly from vehicle, BEACON-agents, 
gefitinib, or the cisplatin-pemetrexed combination lung therapy. Conversely, cisplatin-
etoposide and the targeted inhibitors afatinib and osimertinib improved survival with 
most animals surviving until trial completion for the latter two agents.  




The animal protocol used is the same as in Chapter 3.2.  
Cells 
 The PC-9 parenteral line was provided by Dr. Lori Hazlehurst pre-transduced 
with the pcDNA3.1(+)/Luc2=tdT plasmid. These cells were serially intracardially 
injected and extracted through brains six times to create the PC-9-Br line. Cells were 
grown in a 37C incubator at 5% CO2, and grown in RPMI with 10% fetal bovine serum, 
5% penicillin-streptomycin, and 10-11 μL/mL of G4918 (Geneticin) to ensure plasmid 
expression. All cells used in this experiment are between passages 1 to 10. A549 and 
CCL-185IG were acquired from American Type Culture Collection (ATCC). A549 has a 
KRAS mutation while CCL-185IG is a modified A549 to express the EML4-ALK fusion 
peptide. Hence, A549 will be termed A549N, while CCL-185IG will be termed A549F.  
Stereotactic injection 
 The protocol for intracardiac cell injection is the same as in Chapter 4.2. 
Drugs and dosing 
 The dosing regimen and solubility of cisplatin, etoposide, pemetrexed, gefitinib, 
afatinib, and osimertinib are the same as in section 4.2. The dosing regimen and solubility 
for irinotecan, eribulin, docetaxel, vinorelbine, gemcitabine, and NKTR-102 are the same 
as in Chapter 4.2. These are summarized in Table 6.1.   
Longitudinal bioluminescence 
 Animals were given an intraperitoneal 150 mg/kg injection of d-luciferin 
potassium salt and anesthetized with 2% isoflurane. Based on the results from Chapter 3, 
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after 10 minutes of circulation, animals were transferred to the IVIS Spectra CT 
(PerkinElmer) and bioluminescence (BLI) was captured at auto-exposure and one-minute 
time spans on Stage D with medium binning, fitting within the optimal imaging time for 
the PC-9-Br line (Figure 4.2). BLI was taken twice weekly to measure chemotherapy 
response and tumor burden, performed at least an hour prior to drug administration to 
avoid interactions. For quantification, a region of interest (ROI) was drawn based on 
cranial circumference. BLI based on ROI is reported as radiance 
(photons/sec/cm2/steridian).  
Toxicology 
 MTT in vitro toxicity studies were performed using the same protocol as in 
Chapter 4.2. 
Statistics 
 On survival endpoints, mice were sacrificed and date of death recorded. Kaplan-
Meier curves were generated and compared using log-rank statistics. All statistics were 
performed on GraphPad Prism 6.0 and considered significant at p < 0.05.  
6.3 Results 
PC-9-Br shows the most SN-38 sensitivity of the developing LCBM lines 
In order to determine which cell line to conduct NKTR-102 in vivo, an in vitro 
toxicology study was performed on parenteral lung cancer cells using NKTR-102’s active 
metabolite SN-38. The EGFR-mutant PC-9 showed the highest sensitivity to SN-38 at 7.3 
nM, while the KRAS mutant A549N and ELM4-ALK-expressing A549F were 979 nM and 
6.2 μM, respectively (Fig. 6.1). PC-9-Br was chosen as the model for the NKTR-102 
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efficacy study, along with targeted agents against the exon 19 deleted EGFR receptor it 
possesses. Subsequently, a brain-seeking line was created through 6 passages of 
injections and extractions.  
Non-targeted chemotherapy does not significantly prolong survival of PC-9 
brain metastases compared to vehicle 
The main focus of the study was to evaluate the efficacy of NKTR-102 compared 
to BEACON-specific agents, conventional lung cancer chemotherapy, and targeted 
chemotherapy in the experimental LCBM model. For grouping purposes, outcomes will 
be reported as “non-targeted” (e.g. NKTR-102, BEACON agents, and lung 
chemotherapy) and “targeted” (e.g. EGFR inhibitors). After the injection of 150,000 PC-
9-Br cells into the left ventricle, metastatic lesions were allowed to grow for 21 days prior 
to drug administration and BLI measurements. Thus, 21 days (Week 3) is the baseline to 
normalize further values. BLI was taken twice weekly as a quantitative surrogate for 
tumor burden and chemotherapeutic efficacy.  
In vehicle PC-9-Br animals (Fig. 6.2A), tumor burden increased by 29,400-fold 
from baseline across 8 weeks (Fig. 6.2B). Similarly, gemcitabine increased 28,400-fold, 
eribulin increased 14,800-fold, docetaxel increased 8000-fold, and vinorelbine increased 
400-fold above baseline, and NKTR-102 signal increased by 1870-fold (Fig. 6.2B). The 
BEACON-agents and NKTR-102 featured almost identical increases in tumor burden for 
6 weeks after injection, then separated as survivors who bore lower BLI populated the 
curve (Fig. 6.2B). The similarities of BLI curves are also represented in survival curves. 
Vehicle mice survived for a median of 42 days, with irinotecan-treated mice surviving for 
a median of 42 days, gemcitabine mice surviving for a median of 45.5 days, docetaxel 
171 
 
mice surviving for a median of 42.5 days, eribulin mice surviving for a median of 43.5 
days, vinorelbine mice surviving for a median of 41 days, and NKTR-102 mice surviving 
for a median of 43 days (Fig. 6.3). No significance in median survival was seen with 
BEACON-agents or NKTR-102 compared to vehicle (p < 0.05) (Table 6.2). 
For conventional lung chemotherapy (Fig. 6.4A), cisplatin and pemetrexed-
treated mice had a 4400-fold increase in BLI (Fig. 6.4B) and survived for 45 days (Fig. 
6.5), while cisplatin and etoposide administration increased tumor BLI by 2700-fold (Fig. 
6.4B) and significantly extended median survival to 51.5 days after injection compared to 
vehicle (p < 0.05) (Fig. 6.5). The cisplatin and etoposide combination is the only non-
targeted chemotherapy to significantly extend survival (Table 6.2). Two eribulin mice 
and one NKTR-102 mouse responded to therapy, with the latter excluded from Fig. 6.2B 
due to significantly lowered bioluminescence values. The responder curve is attached as a 
supplementary figure (S1). 
Targeted second- and third-generation tyrosine kinase inhibitors significantly 
prolongs survival in PC-9-Br mice compared to vehicle  
EGFR-targeted inhibitors were administered daily via oral gavage to mice (Fig. 
6.6A). In gefitinib-treated mice, BLI rose in a similar fashion to vehicle-treated mice 
albeit much lower, with a maximum 1200-fold above baseline (Fig. 6.6B). Gefitinib 
median survival was 48 days, which was not significant compared to vehicle (p < 0.05) 
(Fig. 6.7). In contrast, daily administration of the EGFR-inhibitors afatinib and 
osimertinib led to an early and sustained response compared to non-targeted 
chemotherapy and gefitinib. BLI was increased by 100-fold in the afatinib-treated mice 
(Fig. 6.6B) and 8 of 9 mice survived until the end of the trial (Fig. 6.7), and in the 
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osimertinib-treated group tumor burden increased 300-fold compared to baseline (Fig. 
6.6B) with 8 of 9 mice surviving until the end of the trial (Fig. 6.7). Both afatinib and 
osimertinib significantly increased survival compared to vehicle (Table 6.2).  
6.4 Discussion 
  Significant variability exists of a chemotherapy entering peripheral tissue vs. the 
brain. This may be due to the brain being a “sanctuary site” for metastases, due to the 
presence of the blood-brain and blood-tumor barriers.  
Platinum-based therapy, including cisplatin-etoposide and cisplatin-pemetrexed, 
have shown limited efficacy in multiple Phase II trials involving EGFR-mutated LCBM. 
[8] Platinum doublet therapy has largely been replaced by the use of targeted inhibitors. 
It was shown that gefitinib was superior to carboplatin-pemetrexed therapy in 
prolonging progression-free survival in EGFR-mutated brain metastases. [11] Despite 
being substrates for P-glycoprotein efflux, it was demonstrated that erlotinib [12] and 
gefitinib [13] enter the brain metastatic parenchyma and numerous case reports depict 
prolonged survival and positive outcomes using these first-line EGFR-tyrosine kinase 
inhibitors. [14, 15] Similarly, afatinib is a substrate for P-glycoprotein [16] and has 
shown some clinical benefit in the LUX-Lung 3 and LUX-Lung 6 trials, where there was 
an overall 2.8-month increase in progression-free survival. [17] Osimertinib, the only 
third-generation EGFR TKI, has been shown to penetrate and accumulate in brain tissue, 
[13] with the FLAURA trial showing osimertinib having a superior progression-free 
survival compared to standard of care. [18]   
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 It is unclear as to why NKTR-102 did not show an improvement in median 
survival compared to either other non-targeted agents or targeted inhibitors. NKTR-102 is 
shown to penetrate the blood-tumor barrier and accumulate in tumors to provide a 
sustained cytotoxic exposure to the topoisomerase I inhibitor SN-38. [19] NKTR-102 
improved survival in two models of BCBM (Chapter 4) compared to BEACON therapy 
and preliminary evidence shows its efficacy in the glioblastoma model (Chapter 7). The 
use of irinotecan in small cell lung cancer brain metastases is documented, though its use 
in NSCLC brain metastases is not documented. 
It is hypothesized that NKTR-102 works best in large, slow-growing tumors. 
Median survival for PC-9-Br in this study (42 days) is similar to the median survival for 
the MDA-MB-231-Br (38 days) and longer than the JIMT-1-Br (28 days) BCBM vehicle 
groups (Chapter 4). PC-9-Br tumors are smaller and more numerous than either BCBM 
tumor types, which may limit the ability of NKTR-102 to sufficiently act in a depot 
fashion.  
It is also unclear why gefitinib failed to improve median survival in this 
preclinical model when reports of its efficacy exists in the clinical setting. It is possible 
that the dose used was insufficient to penetrate into tumor parenchyma. A recent paper 
utilizing gefitinib, afatinib, and osimertinib in the PC-9 model of brain metastases was 
published and the doses inside are used in our model. In this paper, gefitinib was dosed at 
6.25 mg/kg and showed no effect on improving median survival compared to control [13] 
while another paper utilized gefitinib at 40 mg/kg in their preclinical PC-9 brain tumor 
model and showed great improvements in median survival compared to vehicle therapy. 
[20] Similarly, afatinib was dosed at 7.5 mg/kg [13] while another paper utilized afatinib 
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at 15 to 30 mg/kg in their preclinical PC-9 brain tumor model. [16] We opted to use the 
higher afatinib dosing but performed our study prior to the higher gefitinib dosing 
publication, which if followed may have had vastly different results. 
6.5 Conclusion 
While etirinotecan pegol shows efficacy in preclinical models of breast-brain 
metastases and glioblastoma, it does not improve median survival compared to vehicle or 
conventional chemotherapy in a preclinical EGFR-mutated lung cancer model. The 
second- and third-generation tyrosine kinase inhibitors show early tumor burden control 
which eventually shows resistance, mimicking the effects of continuous dosing seen in 
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Figure 6.1. Sensitivity to SN-38 for three brain-seeking lung cancer lines.  
Increasing concentrations of SN-38 were used to create a cytotoxicity assay curve. The 
EGFR-mutant PC-9 shows the greatest sensitivity to SN-38. Data presented is based on 









Figure 6.2. Bioluminescence in PC-9-Br treated with BEACON therapy. 
(A) BEACON-treated mice do not stop tumor growth in PC-9-Br cells. (B) 




Figure 6.3. Kaplan-Meier survival curve of PC-9-Br mice treated with etirinotecan 
pegol and BEACON-based chemotherapy. 
 On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle 
(saline, n = 10), docetaxel (10 mg/kg, n = 10), vinorelbine (10 mg/kg, n = 9), eribulin (1.5 
mg/kg, n = 10), gemcitabine (60 mg/kg, n = 10), irinotecan (50 mg/kg, n = 10) or 
etirinotecan pegol (50 mg/kg, n = 10). Median survival time were 42 days for vehicle, 
42.5 days for docetaxel, 41 days for vinorelbine, 43.5 days for eribulin, 45.5 days for 
gemcitabine, 42 days for irinotecan, and 43 days for etirinotecan pegol. Etirinotecan 
pegol did not improve median survival compared to vehicle or other BEACON 








Figure 6.4. Bioluminescence in conventional lung chemotherapy in the PC-9-Br 
model. 
(A) Longitudinal imaging shows tumor burden increases similarly in vehicle- and 






Figure 6.5. Kaplan-Meier survival curve of PC-9-Br mice treated with conventional 
lung chemotherapy.  
On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle 
(saline, n = 10), combined cisplatin-etoposide (n = 10), or combined cisplatin-pemetrexed 
(n = 9). Median survival time was 42 days for vehicle, 51.5 days for cisplatin-etoposide, 
and 45 days for cisplatin-pemetrexed. Cisplatin-etoposide significantly improved median 
survival compared to vehicle (p < 0.05), though cisplatin-pemetrexed did not (p > 0.05). 







Figure 6.6. Bioluminescence profiles of EGFR-inhibitors in the PC-9-Br model. 
(A) While gefitinib does not control tumor burden compared to vehicle therapy, afatinib 
and osimertinib control tumor burden until the end of the trial. (B) All targeted inhibitors 
show reduced bioluminescence signaling compared to vehicle therapy, though afatinib 
and osimertinib show early and sustained tumor control, with drug resistance occurring at 





Figure 6.7. Kaplan-Meier survival curve of PC-9-Br mice treated with targeted lung 
chemotherapy.  
On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle 
(saline, n = 10), gefitinib (n = 9), afatinib (n = 9), or osimertinib (n = 8). Median survival 
time was 42 days for vehicle, 48 days for gefitinib, and undefined for afatinib and 
osimertinib. One mouse each died in the afatinib and osimertinib groups not due to tumor 
or drug toxicity, and were counted in the statistics. Gefitinib did not improve median 
survival compared to vehicle (p > 0.05), but both afatinib and osimertinib significantly 
improved median survival (p < 0.05) with all but one mouse surviving until the end of the 






Supplemental Figure 6.1. Bioluminescence curves of conventional chemotherapy 
responders. 
Two eribulin- and one NKTR-102-treated mice responded to therapy and showed a 
decrease in tumor burden. This did not impact the overall median survival of the groups.
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Drug Source Dose Formulation Administration 
Afatinib SelleckChem 30 
mg/kg 
5% DMSO, 10% 
polyethylene glycol 400, 
85% distilled water 
PO, every day 




IV, every 7 days 
Docetaxel SelleckChem 10 
mg/kg 
5% Ethanol, 5% Tween 
80, 90% saline 
IV, every 7 days 




Pegylated liposomes in 
5% dextrose 





5% ethanol, 15% 
distilled water, 80% 
saline 







Saline IV every 7 days 
Etoposide SelleckChem 10 
mg/kg 
5% DMSO, 5% Tween 
80, 90% Saline 
IV on days 2-5 
from cisplatin 
administration 
Gefitinib SelleckChem 6.25 
mg/kg 
5% DMSO, 10% 
polyethylene glycol 400, 
85% distilled water 
PO every day 
Gemcitabine SelleckChem 60 
mg/kg 







5% Dextrose IV, every 7 days 
Osimertinib SelleckChem 25 
mg/kg 
5% DMSO, 10% 
polyethylene glycol 400, 
85% distilled water 
PO, every day 
Pemetrexed SelleckChem 100 
mg/kg 
Saline IV, on days 3, 4, 
5 from cisplatin 
administration 
Vinorelbine SelleckChem 10 
mg/kg 
Saline IV, every 7 days 













Vehicle 42 10 0  
Irinotecan 42 9 0 0.6720 
NKTR-102 43 10 1 (10%) 0.1609 
Gemcitabine 45.5 10 0 0.1055 
Docetaxel 42.5 10 0 0.7636 
Eribulin 43.5 10 2 (20%) 0.1246 
Vinorelbine 41 9 0 0.2364 
CONVENTIONAL LUNG CHEMOTHERAPY AGENTS 
Cisplatin + 
Etoposide 
51.5 10 0 0.0331* 
Cisplatin + 
Pemetrexed 
45 9 0 0.2626 
EGFR-TYROSINE KINASE INHIBITOR AGENTS 
Gefitinib 48 10 0 0.1336 
Afatinib (73) 9 8 (89%) < 0.001 ** 
Osimeritinib (73) 8 7 (88%) < 0.001 ** 
Table 6.2. Survival data of NKTR-102 against chemotherapy in the PC-9-Br model. 





PRELIMINARY DATA OF ETIRINOTECAN PEGOL (NKTR-102) 
EFFICACY IN A PRECLINICAL GLIOBLASTOMA MODEL 
7.1 Introduction 
Primary brain malignancies make up a smaller but significant portion of brain 
tumors compared to brain metastases. Within primary brain tumors, almost 80% are 
gliomas, with glioblastoma representing the most aggressive, invasive, and fatal subtype. 
[1] On diagnosis, many patients have an advanced disease state featuring a large, 
heterogeneously distributed tumor on imaging. The symptoms and mortality of 
glioblastoma is due to mass effect and compression on tissues, such as the brainstem. [2]  
Current treatment options for glioblastoma include either whole-brain or 
stereotactic radiation combined with surgical evacuation, with chemotherapy used to 
reduce tumor burden. [3] Temozolomide is the most utilized therapy in glioblastoma [4] 
and many chemotherapy trials use temozolomide as a backbone as combination therapy. 
Other therapy for glioblastoma include Gliadel® (carmustine wafers) [5] and a new 
device Optune®, a non-invasive tumor-treating field therapy. [6] Investigational therapy 
includes photodynamic therapy (NCT03048240), antibody therapy (NCT03139916), 
sonic hedgehog pathway inhibition (NCT03466450), and pegylated chemotherapy. [7] 
Though glioblastoma is typically rapid-growing, the U251 model has exhibited 
more than a 50-day median survival in multiple models. [8, 9] As we have demonstrated 
earlier, a novel PEGylated form of irinotecan has been shown to work on the larger and 
slow-growing MDA-MB-231 triple-negative and HER2+ JIMT1 breast cancer brain 
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metastases models (Chapter 4), but not the more rapidly growing and smaller 4T1 breast 
cancer or PC-9 lung cancer brain metastases models (Chapter 6). It is thought that 
NKTR-102 accumulates in tumors and provides sustained chemotherapy effects 
throughout its long half-life. [10] 
Herein, we report the preliminary survival efficacy of NKTR-102 in the 
intracranial U251 glioblastoma model. A dose of 50 mg/kg NKTR-102 allowed 7 of 8 
treated mice to survive until the end of our trial at 100 days, while vehicle-treated mice 
had a median survival of 73 days. Tumor burden was controlled and minimized within 
one week of NKTR-102 therapy initiation and remained below treatment initiation levels 
throughout the trial. This supports the use of NKTR-102 in the treatment of slow-growing 
glioblastomas.  
7.2 Methods and Materials 
Animals 
 The animal protocol used is the same as in Chapter 4.2. 
Cells 
 The original U251 cell line was provided by Dr. Gordon Meares. A lentivirus 
containing Firefly luciferase (Fluc) with the hygromycin selection marker was purchased 
from Biosettia (GlowCell-16h). 10 μL of viral vector and 10 μL of polybrene (Santa 
Cruz, sc-134220) was added to each well in a 6-well plate of U251 cells at 70% 
confluence. Plates were spun at 1000 RPM for 60 minutes and placed in a 37C incubator 
overnight. The following morning, cells were washed with phosphate-buffer saline (PBS) 
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and then introduced to hygromycin at a concentration of 10 μL/mL in media to ensure 
successful transduction.  After a week, selected cells checked for luciferase expression.  
Intracranial injection 
 Mice were anesthetized under 2% isoflurane and placed in an intracranial 
stereotactic injection device (Stoelting). 500,000 U251 cells were suspended in PBS 
(100,000 per 1 μL) and injected over 5 minutes. 1 μL was injected every 45 seconds for 4 
μL, after a minute pause to let cells distribute, the last 1 μL was injected and the syringe 
was pulled out after another minute. 
Drugs and dosing 
 NKTR-102 at 50 mg/kg equivalents of irinotecan (11 mg of NKTR-102 per 
mouse) was dissolved in PBS for a total of 200 μL/mouse. PBS was used as the vehicle. 
Doses were administered weekly via tail vein to an anesthetized mouse, starting on Day 
49.  
Bioluminescence imaging  
The bioluminescence imaging protocol used is the same from Chapter 5.2. The 
timing of injection is based on the pharmacokinetic profiling of Chapter 3. 
In vitro toxicology 
 The toxicology protocol used is the same from Chapter 4.2.  
7.3 Results 
U251 glioblastoma cells are sensitive to SN-38 in the nanomolar range 
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When exposed to 1 femtomolar to 1 millimolar concentrations, the IC50 value of 
U251 cells to SN-38, the active metabolite of NKTR-102, was 0.536 nM (Fig. 7.1). This 
is lower than in the MDA-MB-231-Br model (10.5 nM), 4T1-Br model (24.9 nM), JIMT-
1 model (222.8 nM) (Table 4.2), or PC-9-Br model (6.0 uM) (Fig. 6.1).  
NKTR-102 controls tumor burden in the preclinical U251 glioblastoma model 
Having seen that NKTR-102 improves survival in the preclinical breast-brain 
metastatic model due to accumulation in tumors, we then evaluated its efficacy in a 
glioblastoma model. U251 cells were intracranially injected and allowed to grow for 49 
days (baseline), at which animals were randomized to either vehicle or NKTR-102. BLI 
was taken twice weekly to monitor tumor burden and chemotherapy response (Fig. 7.2). 
In vehicle animals, tumor burden increased 103-fold over baseline across 7 weeks, while 
in weekly-treated NKTR-102 50 mg/kg, tumor burden was controlled from initiation and 
reduced 5-fold over the same time span (Fig. 7.3A). Survival reflected BLI, as median 
survival in vehicle was 73 days, with all but one mouse administered with NKTR-102 
surviving until the end of the 100-day trial (Fig. 7.3B). Of interest, NKTR-102 provided 
sustained tumor burden control but did not eliminate BLI signal in any mouse despite 7 
weeks of dosing.  
7.4 Discussion 
As the U251 had the most sensitivity to SN-38 of all cell lines tested (Table 4.2, 
Table 6.2, Fig. 7.1), it was hoped that NKTR-102 administration would lead to 
significant survival benefit and better outcomes than any previous model. This study 
shows that weekly NKTR-102 successfully controls tumor burden and improves survival 
in an intracranial glioblastoma model compared to vehicle therapy.  
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The efficacy of NKTR-102 is now exhibited in three models, the first two being 
triple-negative and HER2+ BCBM. [10][Chapter 4] The reduction of tumor BLI signal 
occurred within one week of NKTR-102 dosing in the glioblastoma model, similar to the 
MDA-MB-231-Br BCBM model (Fig. 3.2), and stayed below baseline for the duration of 
treatment. The survival benefit was significant as NKTR-102 allowed 7 of 8 mice to 
survive until the end of therapy administration.  
The vascularity within glioblastomas are extremely heterogeneous, with central 
cores possessing enhanced permeability while peripheral areas retaining intact 
permeability. [11, 12] This intra-lesion discordance may explain NKTR-102’s ability to 
significantly reduce, but not completely eliminate tumor presence from intracranial 
lesions, even after weeks of dosing.  
The basis for NKTR-102 efficacy relies on two factors: size and permeability. As 
a 20-kDa molecule, NKTR-102 preferentially accumulates into tumor tissue [10] (Fig. 
4.7). Its large size allows the molecule to bypass efflux pumps such as P-glycoprotein; 
present in endothelial and astrocytic components of the BBB and BTB. Retention of the 
molecule within the circulatory system allows for a long half-life, and subsequent 
deposition and residence in tumor parenchyma is a process known as enhanced 
permeation and retention (EPR). [13] 
The permeability of NKTR-102 through leaky vasculature plays a large role in its 
efficacy. [10] Through deposition into tumor tissue and continual release of irinotecan 
with subsequent metabolism to SN-38, NKTR-102 provides substantial and sustained 
cytotoxic effects to reduce tumor burden. The additional advantage of a long circulating 
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half-life provided by pegylation allows for less frequent dosing, which provides another 
advantage over conventional irinotecan dosing. [10] 
In conjunction with EPR, it is possible that NKTR-102 finds its efficacy in slow-
growing and larger tumors. In the preclinical BCBM models, the 231-Br and HER2+ are 
noted to have larger tumors while 4T1 are more numerous, small, and grow relatively 
rapidly. [14] While NKTR-102 improved median survival in the 231-Br and HER2+ 
lines, it did not do so in the 4T1 line (Chapter 4). Similarly, the PC-9-Br line creates 
smaller and rapidly-growing tumors; NKTR-102 administration did not improve median 
survival compared to vehicle in this cell line (Chapter 6). Though tumor size and 
permeability are not related, it is known that glioblastoma form larger tumors and are 
highly permeable compared to metastatic models. [14, 15] In the U251 model, NKTR-
102 may create a depot and provide sustained tumor burden control, though the cellular 
growth may outpace the delivery of drug as evidenced by bioluminescence data. 
With NKTR-102 involved in multiple clinical trials ranging from treatment of 
metastatic breast cancer, including the ATTAIN trial focusing on BCBM, these 
preliminary results show that NKTR-102 causes rapid control of tumor burden from 
primary intracranial lesions with significant survival benefits.  
7.5 Conclusion 
NKTR-102 controls tumor burden and significantly extends survival compared to 
vehicle in the preclinical intracranial U251 glioblastoma model. The next step is to test 
conventional irinotecan and glioblastoma therapy (temozolomide) against NKTR-102 to 
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Figure 7.1. U251 is sensitive to SN-38 in the nanomolar range.  
The dashed line shows a linearity in dose reduction with log-increases of SN-38, while 
the solid line is the non-linear best-fit curve. The U251 glioblastoma cell line is sensitive 




Figure 7.2. NKTR-102 enhances survival compared to vehicle therapy in the U251 
model.  
Following intracranial injection of U251 glioblastoma cells and establishment of brain 
metastases 49 days later, biweekly imaging on the IVIS Spectrum CT tracked tumor 
growth and etirinotecan pegol chemotherapeutic efficacy. Images shown are of the same 
animal sequentially. While vehicle bioluminescence increases until animal death, 















Figure 7.3. Etirinotecan pegol reduces tumor burden and improves survival 
compared to vehicle in the U251 glioblastoma model.  
(A) Mean BLI signal versus time in mice treated with therapy. Treatment was initiated on 
day 49. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden in 
etirinotecan pegol-treated mice was significantly lower than conventional chemotherapy 
or vehicle treatment groups (p < 0.05). (B) Etirinotecan pegol significantly increased 
median survival in tumor mice compared to vehicle, with 9 mice treated with etirinotecan 




PRELIMINARY DATA OF ABRAXANE AND DOXIL EFFICACY IN 
PRECLINICAL BRAIN METASTASES MODELS 
8.1 Introduction 
Metastases remains one of the leading causes of death from cancer. [1] The most 
common organs cancers metastasize to are summed in the mnemonic “BBBLL”: breast, 
bone, brain, liver, and lung. [2] Of these sites, metastases to the brain is the most difficult 
to treat due to the sanctuary state provided by the blood-brain and blood-tumor barriers, 
as well as the difficulty in performing surgical excavations in the small space of a critical 
organ. Though advances have been made in surgery and radiation therapy, significant 
advances have been made in the realm of chemotherapy to treat brain metastases. 
Two current trends exist: to develop new molecules, and to repurpose existing 
molecules into novel dosage forms. Four common repurposing techniques involve 
liposome encapsulation, PEGylation, nanoparticle creation, and antibody conjugation. [3] 
These are often constrained by size to avoid rapid kidney elimination and destruction by 
macrophages. [3] Novel dosage forms may also reduce total amounts of drug required to 
achieve a therapeutic effect, reduce side effects from dosing, and provide sustained 
release of chemotherapy over time. [3] Examples of novel chemotherapeutic agents being 
explored to treat brain metastases include NKTR-102 (etirinotecan pegol), T-DM1 
(trastuzumab emtansine), Abraxane (nano-albumin-bound paclitaxel), and Doxil 
(pegylated liposomal doxorubicin). 
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Abraxane, a 130-nanometer nanoparticle albumin-bound conjugate of paclitaxel, 
(nab-paclitaxel), is FDA-approved for metastatic breast cancer, non-small cell lung 
cancer, and pancreatic cancer. [4, 5] Compared to conventional paclitaxel, nab-paclitaxel 
displays a higher amount of systemic drug exposure, faster possible infusion rates, and 
higher unbound drug due to not requiring Cremophor EL as a cosolvent, slower drug 
elimination, and reduced drug toxicity. [6-8] Its longer half-life may be due to its 
formulation with albumin, which allows albumin-mediated transport of paclitaxel through 
vasculature and into tumor parenchyma. [8]  
Doxil, a pegylated liposomal formulation of doxorubicin, is FDA-approved for 
ovarian cancer and multiple myeloma. [9] Pegylation of liposomes allows reduced 
removal through the spleen and liver, and additionally reduces the amount of drug 
escaping through liposomes and subsequent elimination of free drug. [10] By 
encapsulating doxorubicin into pegylated liposomes, the total amount of drug delivered 
(AUC) and half-life increases almost 30-fold, while clearance drops almost 100-fold, 
when compared to conventional doxorubicin. [10] 
Herein, we show that though the triple-negative breast cancer MDA-MB-231-Br 
cells are more sensitive to Abraxane than Doxil in-vitro, only Doxil significantly 
improves survival in tumor-bearing mice. Doxil does not improve survival in the EGFR-
mutated PC-9 preclinical LCBM model, which corresponds with other studies showing 
only targeted tyrosine kinases improve survival in this setting.  




 The animal protocol used is the same as in Chapter 4.2. 
Cells 
 The MDA-MB-231-Br and PC-9-Br cells used in this Chapter are the same as in 
Chapter 4 and Chapter 5, respectively. 
Tumor cell injection 
 The intracardiac injection protocol used is the same as in Chapter 4.2.  
Drugs and dosing 
 Abraxane was provided as a 1-gram powder of 100 mg paclitaxel to 900 mg 
human albumin. Doses were based on amount of paclitaxel. Weighed powder was then 
suspended in phosphate buffer saline to create a suspension. 50 mg/kg was given weekly 
as an intravenous dose, then 25 mg/kg via intraperitoneal injection 3 to 4 days later. 
Doxil came solubilized at 2 mg per mL and was further diluted in dextrose 5% prior to 
administration at a weekly dose of 6 mg/kg intravenously. [11] 
Statistics 
 Survival data were compared using the log-rank method. Significance is defined 
as p < 0.05. All statistics were performed on GraphPad Prism 6.   
Bioluminescence imaging  
The bioluminescence imaging protocol used is the same from Chapter 4.2.  
In vitro toxicology 




231-Br cells are more sensitive to Abraxane than Doxil 
To test sensitivity of the triple-negative BCBM line 231, the MTT toxicology 
assay was used. Abraxane was suspended initially in PBS and diluted in media. Doxil, 
already provided in solution, was directly added to media and then diluted. The IC50 of 
231-Br to Abraxane is 20.2 nM (Fig. 8.1A), while the IC50 of 231-Br to Doxil is 2.93 
μM (Fig. 8.1B). 
Abraxane improves survival in the preclinical triple-negative breast-brain 
metastatic model 
Abraxane was suspended in PBS and injected via tail vein of mice bearing 231-Br 
metastases 14 days after intracardic cancer cell injection. The median survival was 34.5 
days, while in historical vehicle it was 36.5 days (Fig. 8.2). One mouse in the Abraxane 
group survived until 70 days, whereas no vehicle mice survived until day 50.  
Doxil significantly improves survival over vehicle in the 231-Br model 
Weekly intravenous injections of Doxil starting 14 days post-cancer cell injection 
led to a 670-fold increase in BLI, compared to the nearly 2000-fold increase from 
baseline seen in vehicle mice (Fig. 8.3A). The rate of BLI over time is similar to that of 
vehicle until week 7 of dosing, where the curve represents one surviving mouse. Doxil 
administration improved median survival to of the 231-Br mice to 45 days, 9 more than 
vehicle (p < 0.05) (Fig. 8.3B).  
Doxil does not significantly control tumor growth in the PC-9-Br model 
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As Doxil proved effective in the breast-brain metastatic model, interest turned to 
testing its survival efficacy in the PC-9 lung-brain metastatic model. 21 days after 
intracardiac injection with PC-9 cells, Doxil was intravenously injected at 6 mg/kg 
weekly. Though the BLI rose to only approximately 4500-fold above baseline compared 
to 29000-fold in the vehicle group (Fig. 8.4A), survival was unaffected as both vehicle 
and Doxil-treated groups had a median survival of 42 days (Fig. 8.4B).  
8.4 Discussion 
This is the first study to evaluate survival effects of Abraxane (nano-albumin-
bound paclitaxel) and Doxil (pegylated liposomal doxorubicin) in the setting of brain 
metastases from breast cancer and lung cancer. Our finding for Doxil replicates another 
BCBM study in which survival was improved by 6 days compared to vehicle, though this 
study used the intracranial model of 231-Br. [11] In the clinical setting, Doxil has seen 
efficacy when combined with cyclophosphamide and temozolomide in the settings of 
brain metastases of solid tumors, including breast cancer. 
The in vitro sensitivity of 231-Br to Abraxane is approximately 10-fold lower 
than sensitivity to Doxil, but this does not extrapolate to in vivo effects as survival is 
improved only in the Doxil-treated model. It is possible that albumin-bound drugs are 
unable to escape vasculature as efficiently as liposomes, as protein-binding reduces the 
ability of chemotherapy to penetrate through tight junctions. [12] It was determined that 
the pegylated liposomes of Doxil allow for extravasation through leaky tumor vasculature 
which extended circulation time and enhances drug delivery. [10] In the 231-Br model, 
vasculature is highly heterogenous and tumors are more permeable to smaller (< 200 Da) 
molecules than larger ones (> 500 Da). [13] This may explain our in vivo finding of a 
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chemotherapy nanoparticle being more effective than a albumin-bound chemotherapeutic 
agent, though NKTR-102, a 20-kDa pegylated molecule, has improved survival in this 
same model and was shown to preferentially accumulate inside tumors. [14] 
The lack of survival improvement with Doxil administration in the PC-9 lung-
brain metastatic model is expected, as both conventional chemotherapy and NKTR-102, a 
pegylated form of irinotecan, similarly did not improve survival (Chapter 6). The tumor 
size and permeability characteristics of PC-9-Br are different than that of 231-Br: tumors 
are smaller and moderately permeable to 14C-AIB (Chapter 5). This again may explain 
why a 20-kDa substance did not show survival advantage compared to targeted small 
molecule inhibitors, but does not explain why a 130-nm pegylated liposome failed to do 
so.  
8.5 Conclusion 
Abraxane and Doxil are novel formulations of existing drugs: paclitaxel and 
doxorubicin, respectively. While Abraxane is more potent in-vitro, Doxil controls tumor 
burden and significantly improves survival in the preclinical triple-negative MDA-MB-
231 breast cancer brain metastatic model. Doxil does not control tumor burden or 
significantly improve survival in the PC-9 lung cancer brain metastasis model. These 
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Figure 8.1. In-vitro cytotoxicity of Abraxane and Doxil on MDA-MB-231-Br cells. 






Figure 8.2. MDA-MB-231-Br survival is not improved on Abraxane therapy. 
















Figure 8.3. Doxil bioluminescence and survival effects on MDA-MB-231-Br tumors. 
(A) Bioluminescence in Doxil-treated mice followed a similar albeit lower trend than 
vehicle, which dropped due to surviving mice. (B) Median survival was significantly 















Figure 8.4. Effects of Doxil on the PC-9-Br model. 
(A) Bioluminescence in Doxil-treated mice was not significantly different from vehicle-





CONCLUSION AND FUTURE DIRECTIONS 
9.1 Conclusion 
 In conclusion, this dissertation (a) detailed the optimal imaging times and 
quantifiable intervals of the non-toxic tumor surrogate marker D-luciferin in metastatic 
and primary brain tumors, (b) characterized the creation, passive permeability, efflux 
pump status, and vascularity of a widely-used EGFR-mutant lung cancer cell line, (c) 
evaluated the in-vitro cytotoxicity and in-vivo efficacy of three novel chemotherapeutic 
agents on brain metastases of lung and breast cancer as well as primary glioblastoma, and 
(d) provided a review of the current clinical and preclinical treatment options for breast 
cancer and lung cancer brain metastases, and primary glioblastoma. 
 In order to evaluate the effects of tumor growth and response to chemotherapy, 
transfection of cancer cells with firefly luciferase prior to administration allows for a non-
invasive, rapid, and quantifiable surrogate of tumor burden in a process known as 
bioluminescence. The amount of light produced by cancer cells depends on a multitude of 
factors including method of cancer cell and/or D-luciferin injection, and possibly the 
amount of luciferase transfected in each cell. We found that lung-brain metastases had a 
faster onset to peak bioluminescence and a longer duration of signal, but shorter optimal 
(time > 95% peak luminescence time) compared to two models of breast-brain 
metastases; these breast-brain models were similar to each other in these parameters, 
indicating possible differences due to tissue origin. For intracranially injected 
glioblastoma cells, time-to-peak was even faster and optimal imaging time even shorter 
than lung-brain metastases, and produced more photons of light in a given time frame 
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compared to the three metastatic models. In-vitro bioluminescence correlated nearly 
exactly with in-vivo findings, indicating that same timing and conditions allow for 
streamlining preclinical compound screening. With these results, we are able to 
determine the optimal D-luciferin pharmacokinetics for our longitudinal trials involving 
chemotherapy. 
After determining luciferin pharmacokinetics in clinically relevant models, we 
sought to determine the efficacy of a novel chemotherapeutic agent compared to 
conventional chemotherapy utilizing bioluminescence as a surrogate for tumor burden. In 
the MDA-MB-231 triple-negative breast cancer brain metastases model, the pegylated 
form of irinotecan (etirinotecan pegol) was dosed at 50 mg/kg equivalents of irinotecan 
compared to gemcitabine, docetaxel, vinorelbine, and eribulin components of BEACON 
therapy. Etirinotecan pegol increased median survival compared to vehicle and BEACON 
agents, with four of ten mice surviving until the end of the trial. In the JIMT-1 HER2+ 
model, etirinotecan modestly improved survival compared to lapatinib and vehicle, and 
one mouse survived until the end of the trial. Bioluminescence showed increasing tumor 
burden in all conventional chemotherapy treated mice, with a plateau in etirinotecan 
pegol groups, signifying control of tumor burden. In contrast, the murine 4T1 model 
responded poorly to etirinotecan pegol, with only gemcitabine showing an improvement 
in median survival and tumor burden control compared to vehicle. 
In the PC-9 lung cancer brain metastatic model, neither etirinotecan pegol nor any 
non-targeted conventional chemotherapy improved median survival or featured a 
bioluminescence curve that was significantly different from vehicle therapy. In contrast, 
two targeted EGFR-inhibitors showed early tumor burden control which was sustained 
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until the end of the trial, with only one mouse dying of drug administration in each group. 
It is possible that the third targeted agent would improve survival if used at a higher dose. 
A preliminary intracranial U251 glioblastoma model revealed etirinotecan pegol having a 
similar early tumor burden control and improvement in survival compared to the vehicle 
group, with only one mouse dying until the end of trial. These findings pose the 
hypothesis that etirinotecan pegol may work best in slower growing and larger brain 
tumors. 
While the breast-brain metastatic models and glioblastoma cell line have been 
extensively characterized, sufficient data does not exist for lung-brain metastases. Taken 
from terminally ill animals in the aforementioned study, a passive permeability marker 
(14C-AIB), vascularity marker (ICG), and P-glycoprotein marker (OG) were used to 
determine characteristics of the PC-9 brain metastatic model. Fold increases compared to 
non-tumor regions were analyzed. It was found that P-glycoprotein is expressed in the 
PC-9-Br line which may explain the lack of efficacy in conventional chemotherapeutic 
agents. Vascularity is increased in regions of tumor, indicating that typical neoplastic 
angiogenesis occurs, which may be targeted by such agents as Notch-4 inhibitors and 
bevacizumab. Finally, 14C-AIB permeability was increased to levels similar to that of 
breast-brain metastases, and lower values of passive permeability were associated with 
therapy that increased median survival. Tumor size and fold increases in markers were 
not correlated, much like in the breast-brain models. Lastly, smaller tumor sizes were 
associated with therapy that increased median survival. 
With the efficacy of etirinotecan pegol in three cancer lines established, two other 
novel chemotherapeutic agents were evaluated in these models. Pegylated liposomal 
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doxorubicin improved median survival over vehicle in the MDA-MB-231 model, but not 
the PC-9 model. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) did not improve 
survival in the MDA-MB-231 model.  
9.2 Future Studies 
Future studies, based on the results within this dissertation, include: 
1. We have found that pegylated irinotecan (etirinotecan pegol) crosses the BTB 
and preferentially accumulates in tumors of breast-brain metastases, acting as 
a depot and providing sustained SN-38 levels. When compared to 
conventional chemotherapy and vehicle, etirinotecan pegol significantly 
prolonged survival and controlled tumor burden. A Phase 3 clinical study with 
etirinotecan pegol is recruiting patients to correlate these findings in breast 
cancer patients with brain metastases (NCT02915744). Unfortunately, 
etirinotecan pegol did not extend survival in the preclinical EGFR-mutated 
lung-brain metastatic line compared to conventional lung cancer therapy, or 
newly introduced targeted EGFR inhibitors. We also found that etirinotecan 
pegol has similar effects in a preclinical intracranial glioblastoma model 
compared to vehicle therapy. Future studies with etirinotecan pegol should 
evaluate its efficacy in the preclinical EML4/ALK fusion (NCI-H2228, 
NCI-H3122) and KRAS mutated (A549) lung cancer models, as well as its 
efficacy compared to conventional glioblastoma chemotherapy. 
2. We observed that the EGFR-mutated PC-9-Br lung-breast metastatic model is 
similarly permeable to the passive diffusion marker 14C-AIB as some 
preclinical breast-brain metastatic models, despite being significantly smaller. 
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Smaller tumor volumes and lower 14C-AIB permeability is associated with 
therapy that prolongs median survival. The presence of efflux pumps such as 
P-glycoprotein is prominent in the PC-9-Br line and inhibits chemotherapy 
from entering tumor regions. Future studies should evaluate 14C-AIB 
permeability and efflux pump effects on chemotherapy in the preclinical 
EML4/ALK fusion (NCI-H2228, NCI-H3122) and KRAS mutated (A549) 
lung cancer models, and evaluate if drug therapy changes tumor 
properties. 
3. We observed that while albumin-bound paclitaxel (Abraxane) did not improve 
median survival in the preclinical 231-Br model, pegylated liposomal 
doxorubicin (Doxil) extended median survival by nearly 20%. Conversely, 
Doxil had no effect on median survival in the PC-9-Br model. Future studies 
should evaluate Doxil in the HER2+ breast-brain metastatic model, 
EML4/ALK fusion (NCI-H2228, NCI-H3122) and KRAS mutated (A549) 
lung cancer models, and glioblastoma. 
Current therapeutic options for treating brain metastases include surgery, whole-brain or 
stereotactic radiosurgery, and chemotherapy. Incremental advances have improved 
radiation therapy, but significant advances have been made in chemotherapy. The 
creation of targeted chemotherapy against oncogenic mutations, especially those that 
penetrate the blood-brain and blood-tumor barriers, have clinically demonstrated 
improvements in median survival in both in-vivo and patient settings. In combination 
with novel chemotherapeutic dosage forms, the outlook of brain metastases treatment is 
promising. 
